[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f78XCic4Ka34u2ocWzM1hJrBUwR7mIhBTc07mo6C53Nk":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"CSL Behring",[4],144,false,21,57,37478,20,8,[14,17,20,22,25,27,30,32],{"name":15,"count":16},"Hemophilia B",14,{"name":18,"count":19},"Von Willebrand Disease",7,{"name":21,"count":19},"Hemophilia A",{"name":23,"count":24},"Hereditary Angioedema",6,{"name":26,"count":24},"Primary Immune Deficiency",{"name":28,"count":29},"Common Variable Immunodeficiency",5,{"name":31,"count":29},"Hereditary Angioedema Types I and II",{"name":33,"count":34},"Chronic Inflammatory Demyelinating Polyneuropathy",4,[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT06806657","Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching to Garadacimab","2026-06-23","Garadacimab",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT07076446","An Open-label, Multicenter Study to Assess the Pharmacokinetics (PK), Safety, and Tolerability of Subcutaneous IgPro20 in Immunoglobulin (IG) Treatment-naïve Participants With Primary Immunodeficiency (PID)","2026-06-30","IgPro",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT06738485","Recombinant Single-chain Factor VIII (rVIII-SingleChain) in Chinese Participants With Hemophilia A Previously Treated With FVIII Products","2026-10-26","Recombinant single-chain factor VIII",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT07094087","Efficacy and Safety of 4F-PCC (4-Factor Prothrombin Complex Concentrate) in Adult Patients Undergoing Complex Cardiovascular Surgery With Cardiopulmonary Bypass (CPB)","2026-11-18","BE1116",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT06399289","Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Chinese Subjects With Hemophilia B Previously Treated With FIX Therapy","2026-12-01","Recombinant fusion protein linking coagulation factor IX with albumin",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT07619820","A Phase 1b Study to Evaluate the PK of CSL300 (Clazakizumab) in Chinese Subjects With End Stage Kidney Disease (ESKD)","2027-08-30","CSL300",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06617897","Phase 3 Study of Fibrinogen Concentrate (CSL511) in Subjects With Pseudomyxoma Peritonei Undergoing Cytoreductive Surgery","2027-09-01","CSL511 Fibrinogen concentrate",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT06699849","Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis","2027-10-22","CSL889",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT04672733","Hizentra® in Inflammatory Neuropathies - pHeNIx Study","2027-12","Hizentra",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT07048262","Dose Range Finding, Efficacy, and Safety Study of Nebulized CSL787 in Adults With Non-cystic Fibrosis Bronchiectasis (NCFB)","2028-02-28","CSL787",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,162,194,214,242,273,306,353,388,409,429,447,465,497,534,564,588,633,661,679,699,770,803,828,852,878,902,926,948,994,1037,1075,1115,1156,1196,1230,1264,1301,1333,1371,1402,1420,1446,1468,1486,1511,1536,1562,1580,1598,1616,1638,1656,1680,1706,1731,1749,1771,1827,1871,1915,1949,1978,2003,2026,2051,2075,2093,2111,2129,2152,2176,2201,2219,2237,2255,2273,2295,2313,2331,2349,2367,2385,2403,2435,2460,2481,2503,2525,2543,2569,2587,2611,2629,2655,2673,2691,2716,2740,2817,2850,2882,2908,2926,2950,2972,2996,3019,3043,3061],{"intervention":95,"totalTrials":29,"cells":96},"IgPro10",{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":125,"PHASE4":137,"NA":160},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[104,114],{"nctId":105,"briefTitle":106,"status":107,"phases":108,"primaryCompletion":109,"completion":109,"start":110,"enrollment":99,"conditions":111,"interventions":113},"NCT04138485","Efficacy and Safety of IgPro10 in Adults With Systemic Sclerosis (SSc)","WITHDRAWN",[89],"2020-09-16","2019-12-20",[112],"Diffuse Cutaneous Systemic Sclerosis",[95],{"nctId":115,"briefTitle":116,"status":117,"phases":118,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":122,"interventions":123},"NCT04137224","Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)","COMPLETED",[89],"2022-05-17","2019-09-19",27,[112],[124,95],"IgPro20",{"trials":126,"activeCount":99},[127],{"nctId":128,"briefTitle":129,"status":117,"phases":130,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":134,"interventions":136},"NCT01545076","Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) and Treatment With Subcutaneous Immunoglobulin (IgPro20)",[90],"2016-09","2012-03",208,[33,135],"Polyradiculoneuropathy",[124,95,124],{"trials":138,"activeCount":159,"soonestReadout":144},[139,150],{"nctId":140,"briefTitle":141,"status":142,"phases":143,"primaryCompletion":144,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":149},"NCT03684018","Two Dose Levels of Privigen in Pediatric CIDP","RECRUITING",[91],"2029-12-20","2019-02-28",30,[148],"Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",[95],{"nctId":151,"briefTitle":152,"status":117,"phases":153,"primaryCompletion":154,"completion":154,"start":155,"enrollment":9,"conditions":156,"interventions":158},"NCT01390649","A Safety Study of Intravenous Immunoglobulin in Patients With Chronic Immune Thrombocytopenic Purpura (ITP)",[91],"2014-09","2011-11",[157],"Immune Thrombocytopenic Purpura",[95],1,{"trials":161,"activeCount":99},[],{"intervention":40,"totalTrials":163,"cells":164},2,{"EARLY_PHASE1":165,"PHASE1":167,"PHASE2":169,"PHASE3":181,"PHASE4":183,"NA":192},{"trials":166,"activeCount":99},[],{"trials":168,"activeCount":99},[],{"trials":170,"activeCount":99},[171],{"nctId":172,"briefTitle":173,"status":117,"phases":174,"primaryCompletion":175,"completion":175,"start":176,"enrollment":177,"conditions":178,"interventions":180},"NCT05130970","Garadacimab Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis",[89],"2024-01-02","2022-02-03",81,[179],"Idiopathic Pulmonary Fibrosis",[40],{"trials":182,"activeCount":99},[],{"trials":184,"activeCount":159,"soonestReadout":39},[185],{"nctId":37,"briefTitle":38,"status":186,"phases":187,"primaryCompletion":39,"completion":39,"start":188,"enrollment":189,"conditions":190,"interventions":191},"ACTIVE_NOT_RECRUITING",[91],"2025-04-28",18,[23],[40],{"trials":193,"activeCount":99},[],{"intervention":45,"totalTrials":159,"cells":195},{"EARLY_PHASE1":196,"PHASE1":198,"PHASE2":200,"PHASE3":202,"PHASE4":204,"NA":212},{"trials":197,"activeCount":99},[],{"trials":199,"activeCount":99},[],{"trials":201,"activeCount":99},[],{"trials":203,"activeCount":99},[],{"trials":205,"activeCount":159,"soonestReadout":44},[206],{"nctId":42,"briefTitle":43,"status":186,"phases":207,"primaryCompletion":44,"completion":44,"start":208,"enrollment":12,"conditions":209,"interventions":211},[91],"2025-07-15",[210],"Primary Immunodeficiency",[45],{"trials":213,"activeCount":99},[],{"intervention":215,"totalTrials":159,"cells":216},"CE1226",{"EARLY_PHASE1":217,"PHASE1":219,"PHASE2":221,"PHASE3":223,"PHASE4":225,"NA":240},{"trials":218,"activeCount":99},[],{"trials":220,"activeCount":99},[],{"trials":222,"activeCount":99},[],{"trials":224,"activeCount":99},[],{"trials":226,"activeCount":159,"soonestReadout":232},[227],{"nctId":228,"briefTitle":229,"status":230,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":239},"NCT07326592","Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza \u002F Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)","NOT_YET_RECRUITING",[91],"2033-09-15","2026-07-20",270,[236,237,238],"Alpha1 Antitrypsin Deficiency","Alpha1-Proteinase Inhibitor Deficiency","Emphysema",[215],{"trials":241,"activeCount":99},[],{"intervention":65,"totalTrials":163,"cells":243},{"EARLY_PHASE1":244,"PHASE1":246,"PHASE2":255,"PHASE3":257,"PHASE4":269,"NA":271},{"trials":245,"activeCount":99},[],{"trials":247,"activeCount":159,"soonestReadout":64},[248],{"nctId":62,"briefTitle":63,"status":230,"phases":249,"primaryCompletion":64,"completion":250,"start":44,"enrollment":251,"conditions":252,"interventions":254},[88],"2027-11-30",24,[253],"End Stage Kidney Disease (ESKD)",[65],{"trials":256,"activeCount":99},[],{"trials":258,"activeCount":159,"soonestReadout":263},[259],{"nctId":260,"briefTitle":261,"status":142,"phases":262,"primaryCompletion":263,"completion":263,"start":264,"enrollment":265,"conditions":266,"interventions":268},"NCT05485961","Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)",[89,90],"2029-05-22","2022-10-21",3110,[267],"Atherosclerotic Cardiovascular Disease in Patients With ESKD",[65],{"trials":270,"activeCount":99},[],{"trials":272,"activeCount":99},[],{"intervention":274,"totalTrials":163,"cells":275},"CSL222",{"EARLY_PHASE1":276,"PHASE1":278,"PHASE2":280,"PHASE3":282,"PHASE4":302,"NA":304},{"trials":277,"activeCount":99},[],{"trials":279,"activeCount":99},[],{"trials":281,"activeCount":99},[],{"trials":283,"activeCount":163,"soonestReadout":296},[284,292],{"nctId":285,"briefTitle":286,"status":142,"phases":287,"primaryCompletion":288,"completion":288,"start":289,"enrollment":11,"conditions":290,"interventions":291},"NCT07080905","Phase 3, Open-label, Single-dose Study of CSL222 in Adolescent Male Subjects (≥ 12 to < 18 Years of Age) With Severe or Moderately Severe Hemophilia B",[90],"2033-10-24","2025-07-28",[15],[274],{"nctId":293,"briefTitle":294,"status":142,"phases":295,"primaryCompletion":296,"completion":297,"start":298,"enrollment":299,"conditions":300,"interventions":301},"NCT06003387","Efficacy and Safety of CSL222 (Etranacogene Dezaparvovec) Gene Therapy in Adults With Hemophilia B With Pretreatment Adeno-associated Virus Serotype 5 (AAV5) Neutralizing Antibodies (Nabs)",[90],"2028-10-04","2032-04-02","2024-01-30",35,[15],[274],{"trials":303,"activeCount":99},[],{"trials":305,"activeCount":99},[],{"intervention":55,"totalTrials":307,"cells":308},3,{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":315,"PHASE4":349,"NA":351},{"trials":310,"activeCount":99},[],{"trials":312,"activeCount":99},[],{"trials":314,"activeCount":99},[],{"trials":316,"activeCount":159,"soonestReadout":54},[317,329,340],{"nctId":318,"briefTitle":319,"status":117,"phases":320,"primaryCompletion":321,"completion":322,"start":323,"enrollment":324,"conditions":325,"interventions":328},"NCT02281201","Study of a Prothrombin Complex Concentrate for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Japanese Subjects",[90],"2016-01","2016-03","2014-10",11,[326,327],"Acute Major Bleeding","Reversal of Coagulopathy",[55],{"nctId":330,"briefTitle":331,"status":332,"phases":333,"primaryCompletion":334,"completion":334,"start":335,"enrollment":336,"conditions":337,"interventions":339},"NCT05568888","Evaluation of BE1116 in Patients With Traumatic Injury and Acute Major Bleeding to Improve Survival ( TAP Study )","TERMINATED",[90],"2024-10-29","2023-03-28",1366,[338],"Traumatic Injury",[55],{"nctId":52,"briefTitle":53,"status":142,"phases":341,"primaryCompletion":54,"completion":342,"start":343,"enrollment":344,"conditions":345,"interventions":347},[90],"2026-12-17","2025-09-15",200,[346],"Complex Cardiovascular Surgery With Cardiopulmonary Bypass",[55,348],"FFP",{"trials":350,"activeCount":99},[],{"trials":352,"activeCount":99},[],{"intervention":354,"totalTrials":163,"cells":355},"Cryoprecipitate",{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":360,"PHASE3":362,"PHASE4":384,"NA":386},{"trials":357,"activeCount":99},[],{"trials":359,"activeCount":99},[],{"trials":361,"activeCount":99},[],{"trials":363,"activeCount":159,"soonestReadout":69},[364,376],{"nctId":365,"briefTitle":366,"status":107,"phases":367,"primaryCompletion":368,"completion":368,"start":369,"enrollment":99,"conditions":370,"interventions":374},"NCT00916656","Fibrinogen Concentrate (Human) - Efficacy and Safety Study",[90],"2014-03","2009-10",[371,372,373],"Afibrinogenemia","Hypofibrinogenemia","Fibrinogen Deficiency",[375,354],"Fibrinogen Concentrate, Human",{"nctId":67,"briefTitle":68,"status":142,"phases":377,"primaryCompletion":69,"completion":378,"start":379,"enrollment":380,"conditions":381,"interventions":383},[90],"2027-10-29","2024-10-01",90,[382],"Acquired Fibrinogen Deficiency",[70,354],{"trials":385,"activeCount":99},[],{"trials":387,"activeCount":99},[],{"intervention":50,"totalTrials":159,"cells":389},{"EARLY_PHASE1":390,"PHASE1":392,"PHASE2":394,"PHASE3":396,"PHASE4":405,"NA":407},{"trials":391,"activeCount":99},[],{"trials":393,"activeCount":99},[],{"trials":395,"activeCount":99},[],{"trials":397,"activeCount":159,"soonestReadout":49},[398],{"nctId":47,"briefTitle":48,"status":186,"phases":399,"primaryCompletion":49,"completion":49,"start":400,"enrollment":401,"conditions":402,"interventions":404},[90],"2025-01-09",60,[403],"Congenital Hemophilia A",[50],{"trials":406,"activeCount":99},[],{"trials":408,"activeCount":99},[],{"intervention":60,"totalTrials":159,"cells":410},{"EARLY_PHASE1":411,"PHASE1":413,"PHASE2":415,"PHASE3":417,"PHASE4":425,"NA":427},{"trials":412,"activeCount":99},[],{"trials":414,"activeCount":99},[],{"trials":416,"activeCount":99},[],{"trials":418,"activeCount":159,"soonestReadout":59},[419],{"nctId":57,"briefTitle":58,"status":186,"phases":420,"primaryCompletion":59,"completion":59,"start":421,"enrollment":422,"conditions":423,"interventions":424},[90],"2024-07-28",23,[15],[60],{"trials":426,"activeCount":99},[],{"trials":428,"activeCount":99},[],{"intervention":70,"totalTrials":159,"cells":430},{"EARLY_PHASE1":431,"PHASE1":433,"PHASE2":435,"PHASE3":437,"PHASE4":443,"NA":445},{"trials":432,"activeCount":99},[],{"trials":434,"activeCount":99},[],{"trials":436,"activeCount":99},[],{"trials":438,"activeCount":159,"soonestReadout":69},[439],{"nctId":67,"briefTitle":68,"status":142,"phases":440,"primaryCompletion":69,"completion":378,"start":379,"enrollment":380,"conditions":441,"interventions":442},[90],[382],[70,354],{"trials":444,"activeCount":99},[],{"trials":446,"activeCount":99},[],{"intervention":348,"totalTrials":159,"cells":448},{"EARLY_PHASE1":449,"PHASE1":451,"PHASE2":453,"PHASE3":455,"PHASE4":461,"NA":463},{"trials":450,"activeCount":99},[],{"trials":452,"activeCount":99},[],{"trials":454,"activeCount":99},[],{"trials":456,"activeCount":159,"soonestReadout":54},[457],{"nctId":52,"briefTitle":53,"status":142,"phases":458,"primaryCompletion":54,"completion":342,"start":343,"enrollment":344,"conditions":459,"interventions":460},[90],[346],[55,348],{"trials":462,"activeCount":99},[],{"trials":464,"activeCount":99},[],{"intervention":85,"totalTrials":163,"cells":466},{"EARLY_PHASE1":467,"PHASE1":469,"PHASE2":481,"PHASE3":491,"PHASE4":493,"NA":495},{"trials":468,"activeCount":99},[],{"trials":470,"activeCount":99},[471],{"nctId":472,"briefTitle":473,"status":117,"phases":474,"primaryCompletion":475,"completion":475,"start":476,"enrollment":477,"conditions":478,"interventions":480},"NCT04643587","Study to Assess CSL787 in Non-cystic Fibrosis Bronchiectasis (NCFB)",[88],"2023-03-12","2020-12-07",64,[479],"Noncystic Fibrosis Bronchiectasis (NCFB)",[85],{"trials":482,"activeCount":159,"soonestReadout":84},[483],{"nctId":82,"briefTitle":83,"status":142,"phases":484,"primaryCompletion":84,"completion":485,"start":486,"enrollment":487,"conditions":488,"interventions":490},[89],"2028-03-28","2025-09-03",450,[489],"Non-cystic Fibrosis Bronchiectasis",[85],{"trials":492,"activeCount":99},[],{"trials":494,"activeCount":99},[],{"trials":496,"activeCount":99},[],{"intervention":498,"totalTrials":163,"cells":499},"Vamifeport",{"EARLY_PHASE1":500,"PHASE1":502,"PHASE2":515,"PHASE3":528,"PHASE4":530,"NA":532},{"trials":501,"activeCount":99},[],{"trials":503,"activeCount":99},[504],{"nctId":505,"briefTitle":506,"status":117,"phases":507,"primaryCompletion":508,"completion":509,"start":510,"enrollment":511,"conditions":512,"interventions":514},"NCT06996184","Effect of Food on the Oral Bioavailability of a Prolonged-release Formulation of Vamifeport in Healthy Adults",[88],"2025-07-01","2025-07-04","2025-05-27",28,[513],"Healthy Volunteers",[498],{"trials":516,"activeCount":159,"soonestReadout":521},[517],{"nctId":518,"briefTitle":519,"status":142,"phases":520,"primaryCompletion":521,"completion":522,"start":523,"enrollment":524,"conditions":525,"interventions":527},"NCT07332091","Efficacy and Safety of Vamifeport in Adult Participants With Homeostatic Iron Regulator Gene (HFE)-Related Hereditary Hemochromatosis",[89],"2028-03-06","2028-04-06","2026-01-22",84,[526],"Homeostatic Iron Regulator Gene-related Hereditary Hemochromatosis",[498],{"trials":529,"activeCount":99},[],{"trials":531,"activeCount":99},[],{"trials":533,"activeCount":99},[],{"intervention":75,"totalTrials":163,"cells":535},{"EARLY_PHASE1":536,"PHASE1":538,"PHASE2":549,"PHASE3":558,"PHASE4":560,"NA":562},{"trials":537,"activeCount":99},[],{"trials":539,"activeCount":99},[540],{"nctId":541,"briefTitle":542,"status":117,"phases":543,"primaryCompletion":544,"completion":544,"start":545,"enrollment":511,"conditions":546,"interventions":548},"NCT04285827","Safety of Single Doses of CSL889 in Adult Patients With Sickle Cell Disease",[88],"2023-07-24","2021-05-20",[547],"Sickle Cell Disease",[75],{"trials":550,"activeCount":159,"soonestReadout":74},[551],{"nctId":72,"briefTitle":73,"status":142,"phases":552,"primaryCompletion":74,"completion":74,"start":553,"enrollment":554,"conditions":555,"interventions":557},[89],"2025-08-07",70,[556],"Sickle Cell Disease Vaso-occlusive Crisis",[75],{"trials":559,"activeCount":99},[],{"trials":561,"activeCount":99},[],{"trials":563,"activeCount":99},[],{"intervention":565,"totalTrials":159,"cells":566},"Anumigilimab",{"EARLY_PHASE1":567,"PHASE1":569,"PHASE2":571,"PHASE3":582,"PHASE4":584,"NA":586},{"trials":568,"activeCount":99},[],{"trials":570,"activeCount":99},[],{"trials":572,"activeCount":159,"soonestReadout":577},[573],{"nctId":574,"briefTitle":575,"status":142,"phases":576,"primaryCompletion":577,"completion":577,"start":578,"enrollment":579,"conditions":580,"interventions":581},"NCT07224360","Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)",[89],"2028-06-29","2026-02-02",63,[547],[565],{"trials":583,"activeCount":99},[],{"trials":585,"activeCount":99},[],{"trials":587,"activeCount":99},[],{"intervention":589,"totalTrials":307,"cells":590},"AAV5-hFIXco-Padua",{"EARLY_PHASE1":591,"PHASE1":593,"PHASE2":595,"PHASE3":606,"PHASE4":619,"NA":621},{"trials":592,"activeCount":99},[],{"trials":594,"activeCount":99},[],{"trials":596,"activeCount":99},[597],{"nctId":598,"briefTitle":599,"status":117,"phases":600,"primaryCompletion":601,"completion":602,"start":603,"enrollment":307,"conditions":604,"interventions":605},"NCT03489291","Dose Confirmation Trial of AAV5-hFIXco-Padua",[89],"2018-10-30","2023-09-21","2018-07-24",[15],[589],{"trials":607,"activeCount":99},[608],{"nctId":609,"briefTitle":610,"status":117,"phases":611,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":616,"interventions":617},"NCT03569891","HOPE-B: Trial of AMT-061 in Severe or Moderately Severe Hemophilia B Patients",[90],"2021-09-22","2025-03-19","2018-06-27",67,[15],[589,618],"Factor IX",{"trials":620,"activeCount":99},[],{"trials":622,"activeCount":159,"soonestReadout":628},[623],{"nctId":624,"briefTitle":625,"status":626,"phases":627,"primaryCompletion":628,"completion":628,"start":629,"enrollment":630,"conditions":631,"interventions":632},"NCT05962398","Long-term Follow-up Study of Male Adults With Hemophilia B Previously Treated With Etranacogene Dezaparvovec (CSL222)","ENROLLING_BY_INVITATION",[],"2035-03-23","2023-08-30",56,[15],[589],{"intervention":618,"totalTrials":163,"cells":634},{"EARLY_PHASE1":635,"PHASE1":637,"PHASE2":639,"PHASE3":641,"PHASE4":647,"NA":649},{"trials":636,"activeCount":99},[],{"trials":638,"activeCount":99},[],{"trials":640,"activeCount":99},[],{"trials":642,"activeCount":99},[643],{"nctId":609,"briefTitle":610,"status":117,"phases":644,"primaryCompletion":612,"completion":613,"start":614,"enrollment":615,"conditions":645,"interventions":646},[90],[15],[589,618],{"trials":648,"activeCount":99},[],{"trials":650,"activeCount":159,"soonestReadout":655},[651],{"nctId":652,"briefTitle":653,"status":142,"phases":654,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":658,"interventions":659},"NCT06008938","An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B",[],"2043-08-01","2023-06-15",500,[15],[660,618],"HEMGENIX",{"intervention":660,"totalTrials":159,"cells":662},{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":667,"PHASE3":669,"PHASE4":671,"NA":673},{"trials":664,"activeCount":99},[],{"trials":666,"activeCount":99},[],{"trials":668,"activeCount":99},[],{"trials":670,"activeCount":99},[],{"trials":672,"activeCount":99},[],{"trials":674,"activeCount":159,"soonestReadout":655},[675],{"nctId":652,"briefTitle":653,"status":142,"phases":676,"primaryCompletion":655,"completion":655,"start":656,"enrollment":657,"conditions":677,"interventions":678},[],[15],[660,618],{"intervention":80,"totalTrials":159,"cells":680},{"EARLY_PHASE1":681,"PHASE1":683,"PHASE2":685,"PHASE3":687,"PHASE4":689,"NA":691},{"trials":682,"activeCount":99},[],{"trials":684,"activeCount":99},[],{"trials":686,"activeCount":99},[],{"trials":688,"activeCount":99},[],{"trials":690,"activeCount":99},[],{"trials":692,"activeCount":159,"soonestReadout":79},[693],{"nctId":77,"briefTitle":78,"status":142,"phases":694,"primaryCompletion":79,"completion":79,"start":695,"enrollment":696,"conditions":697,"interventions":698},[],"2022-06-10",100,[33],[80],{"intervention":124,"totalTrials":19,"cells":700},{"EARLY_PHASE1":701,"PHASE1":703,"PHASE2":705,"PHASE3":711,"PHASE4":757,"NA":768},{"trials":702,"activeCount":99},[],{"trials":704,"activeCount":99},[],{"trials":706,"activeCount":99},[707],{"nctId":115,"briefTitle":116,"status":117,"phases":708,"primaryCompletion":119,"completion":119,"start":120,"enrollment":121,"conditions":709,"interventions":710},[89],[112],[124,95],{"trials":712,"activeCount":99},[713,723,734,742,746],{"nctId":714,"briefTitle":715,"status":117,"phases":716,"primaryCompletion":717,"completion":717,"start":718,"enrollment":719,"conditions":720,"interventions":722},"NCT00751621","Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (EU Extension Study)",[90],"2011-12","2008-08",40,[721],"Primary Immunodeficiency (PID)",[124],{"nctId":724,"briefTitle":725,"status":332,"phases":726,"primaryCompletion":727,"completion":728,"start":729,"enrollment":730,"conditions":731,"interventions":733},"NCT06524739","Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS",[90],"2025-06-20","2025-07-11","2024-08-28",16,[732],"Post-COVID Postural Orthostatic Tachycardia Syndrome",[124],{"nctId":735,"briefTitle":736,"status":117,"phases":737,"primaryCompletion":738,"completion":738,"start":739,"enrollment":8,"conditions":740,"interventions":741},"NCT00719680","Extension Study of Subcutaneous Immunoglobulin Human in Patients With Primary Immunodeficiency (PID)",[90],"2010-06","2008-06",[26],[124],{"nctId":128,"briefTitle":129,"status":117,"phases":743,"primaryCompletion":131,"completion":131,"start":132,"enrollment":133,"conditions":744,"interventions":745},[90],[33,135],[124,95,124],{"nctId":747,"briefTitle":748,"status":117,"phases":749,"primaryCompletion":750,"completion":750,"start":751,"enrollment":752,"conditions":753,"interventions":756},"NCT02027701","Extension Study of Maintenance Treatment With Subcutaneous Immunoglobulin (IgPro20) for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)",[90],"2017-07-10","2014-07-30",82,[754,755],"Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","Polyradiculoneuropathy, Chronic Inflammatory Demyelinating",[124],{"trials":758,"activeCount":99},[759],{"nctId":760,"briefTitle":761,"status":117,"phases":762,"primaryCompletion":763,"completion":763,"start":764,"enrollment":765,"conditions":766,"interventions":767},"NCT03033745","Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)",[91],"2018-12-14","2017-02-01",49,[210],[124],{"trials":769,"activeCount":99},[],{"intervention":771,"totalTrials":163,"cells":772},"Vivaglobin",{"EARLY_PHASE1":773,"PHASE1":775,"PHASE2":777,"PHASE3":788,"PHASE4":790,"NA":801},{"trials":774,"activeCount":99},[],{"trials":776,"activeCount":99},[],{"trials":778,"activeCount":99},[779],{"nctId":780,"briefTitle":781,"status":117,"phases":782,"primaryCompletion":783,"completion":783,"start":784,"enrollment":12,"conditions":785,"interventions":787},"NCT00701662","A Study of Purified Human Antibodies Administered Subcutaneously to Patients With Multifocal Motor Neuropathy (MMN)",[89],"2009-01","2007-11",[786],"Multifocal Motor Neuropathy (MMN)",[771],{"trials":789,"activeCount":99},[],{"trials":791,"activeCount":99},[792],{"nctId":793,"briefTitle":794,"status":117,"phases":795,"primaryCompletion":796,"completion":796,"start":797,"enrollment":189,"conditions":798,"interventions":800},"NCT00520494","Efficacy and Safety of Vivaglobin® in Previously Untreated Patients With Primary Immunodeficiency",[91],"2008-10","2007-03",[28,799],"Agammaglobulinemia",[771],{"trials":802,"activeCount":99},[],{"intervention":804,"totalTrials":159,"cells":805},"Alpha1-proteinase inhibitor",{"EARLY_PHASE1":806,"PHASE1":808,"PHASE2":810,"PHASE3":812,"PHASE4":814,"NA":826},{"trials":807,"activeCount":99},[],{"trials":809,"activeCount":99},[],{"trials":811,"activeCount":99},[],{"trials":813,"activeCount":99},[],{"trials":815,"activeCount":99},[816],{"nctId":817,"briefTitle":818,"status":117,"phases":819,"primaryCompletion":820,"completion":820,"start":821,"enrollment":822,"conditions":823,"interventions":825},"NCT00261833","Zemaira in Subjects With Emphysema Due to Alpha1-Proteinase Inhibitor Deficiency",[91],"2012-09","2006-03",180,[824,238],"Alpha1-proteinase Inhibitor Deficiency",[804],{"trials":827,"activeCount":99},[],{"intervention":829,"totalTrials":159,"cells":830},"Voncento",{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":837,"PHASE4":839,"NA":850},{"trials":832,"activeCount":99},[],{"trials":834,"activeCount":99},[],{"trials":836,"activeCount":99},[],{"trials":838,"activeCount":99},[],{"trials":840,"activeCount":99},[841],{"nctId":842,"briefTitle":843,"status":117,"phases":844,"primaryCompletion":845,"completion":845,"start":846,"enrollment":847,"conditions":848,"interventions":849},"NCT02552576","Study of Voncento® in Subjects With Von Willebrand Disease",[91],"2018-02-15","2015-10-05",26,[18],[829],{"trials":851,"activeCount":99},[],{"intervention":853,"totalTrials":159,"cells":854},"Blood coagulation Factor VIII and vWF, human",{"EARLY_PHASE1":855,"PHASE1":857,"PHASE2":859,"PHASE3":861,"PHASE4":863,"NA":876},{"trials":856,"activeCount":99},[],{"trials":858,"activeCount":99},[],{"trials":860,"activeCount":99},[],{"trials":862,"activeCount":99},[],{"trials":864,"activeCount":99},[865],{"nctId":866,"briefTitle":867,"status":117,"phases":868,"completion":869,"start":870,"enrollment":146,"conditions":871,"interventions":875},"NCT00168090","Study of Safety and Efficacy of Antihemophilic Factor\u002FVon Willebrand Factor Complex in Surgical Subjects With Von Willebrand Disease (vWD)",[91],"2006-05","2001-10",[18,872,873,874],"Blood Coagulation Disorders","Blood Platelet Disorders","Hematologic Disease",[853],{"trials":877,"activeCount":99},[],{"intervention":879,"totalTrials":159,"cells":880},"Alpha1- proteinase inhibitor [human]",{"EARLY_PHASE1":881,"PHASE1":883,"PHASE2":885,"PHASE3":887,"PHASE4":889,"NA":900},{"trials":882,"activeCount":99},[],{"trials":884,"activeCount":99},[],{"trials":886,"activeCount":99},[],{"trials":888,"activeCount":99},[],{"trials":890,"activeCount":99},[891],{"nctId":892,"briefTitle":893,"status":117,"phases":894,"primaryCompletion":154,"completion":154,"start":895,"enrollment":896,"conditions":897,"interventions":899},"NCT00670007","Extension Study of Zemaira® i.v. Administration in Subjects With Emphysema Due to alpha1-proteinase Inhibitor Deficiency.",[91],"2008-04",140,[238,898],"Alpha 1-proteinase Inhibitor Deficiency",[879],{"trials":901,"activeCount":99},[],{"intervention":903,"totalTrials":159,"cells":904},"Subcutaneous Immune Globulin",{"EARLY_PHASE1":905,"PHASE1":907,"PHASE2":909,"PHASE3":911,"PHASE4":913,"NA":924},{"trials":906,"activeCount":99},[],{"trials":908,"activeCount":99},[],{"trials":910,"activeCount":99},[],{"trials":912,"activeCount":99},[],{"trials":914,"activeCount":99},[915],{"nctId":916,"briefTitle":917,"status":117,"phases":918,"primaryCompletion":919,"completion":919,"start":920,"enrollment":847,"conditions":921,"interventions":923},"NCT02711228","Study of Immune Deficiency Patients Treated With Subcutaneous Immunoglobulin (IgPro20, Hizentra®) on Weekly and Biweekly Schedules",[91],"2018-01-30","2016-03-15",[26,922],"Secondary Immune Deficiency",[903],{"trials":925,"activeCount":99},[],{"intervention":927,"totalTrials":159,"cells":928},"Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for",{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":935,"PHASE4":937,"NA":946},{"trials":930,"activeCount":99},[],{"trials":932,"activeCount":99},[],{"trials":934,"activeCount":99},[],{"trials":936,"activeCount":99},[],{"trials":938,"activeCount":99},[939],{"nctId":940,"briefTitle":941,"status":117,"phases":942,"primaryCompletion":323,"completion":323,"start":155,"enrollment":943,"conditions":944,"interventions":945},"NCT01467947","Postmarketing Immunogenicity Study in HAE Subjects Treated With Berinert",[91],46,[31],[927],{"trials":947,"activeCount":99},[],{"intervention":949,"totalTrials":34,"cells":950},"Biostate",{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":957,"PHASE4":990,"NA":992},{"trials":952,"activeCount":99},[],{"trials":954,"activeCount":99},[],{"trials":956,"activeCount":99},[],{"trials":958,"activeCount":99},[959,966,974,983],{"nctId":960,"briefTitle":961,"status":117,"phases":962,"primaryCompletion":368,"completion":368,"start":963,"enrollment":11,"conditions":964,"interventions":965},"NCT01224808","Extension Study of Biostate in Subjects With Von Willebrand Disease",[90],"2010-10",[18],[949],{"nctId":967,"briefTitle":968,"status":332,"phases":969,"primaryCompletion":970,"completion":970,"start":971,"enrollment":159,"conditions":972,"interventions":973},"NCT01445197","Study of Biostate for Treatment of Children With Hemophilia A Complicated by Antibody Development",[90],"2013-12","2012-12",[21],[949],{"nctId":975,"briefTitle":976,"status":117,"phases":977,"primaryCompletion":978,"completion":978,"start":979,"enrollment":980,"conditions":981,"interventions":982},"NCT01213446","Study of Biostate® in Children With Von Willebrand Disease",[90],"2013-08","2010-08",17,[18],[949],{"nctId":984,"briefTitle":985,"status":117,"phases":986,"primaryCompletion":987,"completion":987,"start":979,"enrollment":299,"conditions":988,"interventions":989},"NCT01229007","Study of Biostate® in Children With Hemophilia A",[90],"2014-07",[21],[949],{"trials":991,"activeCount":99},[],{"trials":993,"activeCount":99},[],{"intervention":995,"totalTrials":307,"cells":996},"FXIII Concentrate",{"EARLY_PHASE1":997,"PHASE1":999,"PHASE2":1001,"PHASE3":1013,"PHASE4":1033,"NA":1035},{"trials":998,"activeCount":99},[],{"trials":1000,"activeCount":99},[],{"trials":1002,"activeCount":99},[1003],{"nctId":1004,"briefTitle":1005,"status":117,"phases":1006,"primaryCompletion":1007,"completion":1007,"start":1008,"enrollment":1009,"conditions":1010,"interventions":1012},"NCT00883090","A Study of the Use of Factor XIII Concentrate in Patients With Inherited FXIII Deficiency",[89],"2010-04","2009-05",15,[1011],"Factor XIII Deficiency",[995],{"trials":1014,"activeCount":99},[1015,1024],{"nctId":1016,"briefTitle":1017,"status":117,"phases":1018,"primaryCompletion":1019,"completion":1019,"start":1020,"enrollment":1021,"conditions":1022,"interventions":1023},"NCT00885742","A Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency",[90],"2011-04","2009-08",41,[1011],[995],{"nctId":1025,"briefTitle":1026,"status":117,"phases":1027,"primaryCompletion":1028,"completion":1028,"start":1029,"enrollment":1030,"conditions":1031,"interventions":1032},"NCT00945906","An Open Enrollment Study of Factor XIII Concentrate in Subjects With Congenital Factor XIII Deficiency",[90],"2011-08","2009-09",61,[1011],[995],{"trials":1034,"activeCount":99},[],{"trials":1036,"activeCount":99},[],{"intervention":1038,"totalTrials":307,"cells":1039},"rIX-FP",{"EARLY_PHASE1":1040,"PHASE1":1042,"PHASE2":1044,"PHASE3":1046,"PHASE4":1071,"NA":1073},{"trials":1041,"activeCount":99},[],{"trials":1043,"activeCount":99},[],{"trials":1045,"activeCount":99},[],{"trials":1047,"activeCount":99},[1048,1055,1064],{"nctId":1049,"briefTitle":1050,"status":117,"phases":1051,"primaryCompletion":987,"start":1052,"enrollment":579,"conditions":1053,"interventions":1054},"NCT01496274","A Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B",[89,90],"2012-02",[15],[1038],{"nctId":1056,"briefTitle":1057,"status":117,"phases":1058,"primaryCompletion":1059,"completion":1059,"start":1060,"enrollment":1061,"conditions":1062,"interventions":1063},"NCT02053792","A Safety and Efficacy Extension Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia B",[90],"2021-06-02","2014-02-06",97,[15],[1038],{"nctId":1065,"briefTitle":1066,"status":117,"phases":1067,"primaryCompletion":323,"start":1068,"enrollment":121,"conditions":1069,"interventions":1070},"NCT01662531","A Safety, Efficacy and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Children With Hemophilia B",[90],"2013-01",[15],[1038],{"trials":1072,"activeCount":99},[],{"trials":1074,"activeCount":99},[],{"intervention":1076,"totalTrials":307,"cells":1077},"Immunoglobulins Intravenous",{"EARLY_PHASE1":1078,"PHASE1":1080,"PHASE2":1082,"PHASE3":1084,"PHASE4":1111,"NA":1113},{"trials":1079,"activeCount":99},[],{"trials":1081,"activeCount":99},[],{"trials":1083,"activeCount":99},[],{"trials":1085,"activeCount":99},[1086,1095,1104],{"nctId":1087,"briefTitle":1088,"status":117,"phases":1089,"primaryCompletion":895,"completion":895,"start":1090,"enrollment":1091,"conditions":1092,"interventions":1094},"NCT00322556","Safety and Efficacy of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)",[90],"2005-11",55,[799,1093,28],"IgG Deficiency",[1076],{"nctId":1096,"briefTitle":1097,"status":117,"phases":1098,"completion":1099,"start":1100,"enrollment":1101,"conditions":1102,"interventions":1103},"NCT00168012","Efficacy and Safety of Intravenous Immunoglobulin IVIG-F10 in Patients With Primary Immunodeficiencies (PID)",[90],"2005-09","2004-09",42,[799,1093,28],[1076],{"nctId":1105,"briefTitle":1106,"status":117,"phases":1107,"completion":821,"start":1100,"enrollment":1108,"conditions":1109,"interventions":1110},"NCT00168025","Efficacy and Safety of Intravenous Immunoglobulin IgPro10 in Patients With Primary Immunodeficiencies (PID)",[90],89,[799,1093,28],[1076],{"trials":1112,"activeCount":99},[],{"trials":1114,"activeCount":99},[],{"intervention":1116,"totalTrials":307,"cells":1117},"rVIII-SingleChain",{"EARLY_PHASE1":1118,"PHASE1":1120,"PHASE2":1122,"PHASE3":1124,"PHASE4":1152,"NA":1154},{"trials":1119,"activeCount":99},[],{"trials":1121,"activeCount":99},[],{"trials":1123,"activeCount":99},[],{"trials":1125,"activeCount":99},[1126,1133,1143],{"nctId":1127,"briefTitle":1128,"status":117,"phases":1129,"primaryCompletion":1130,"completion":1130,"start":368,"enrollment":524,"conditions":1131,"interventions":1132},"NCT02093897","Pharmacokinetic, Efficacy, and Safety Study of Recombinant Factor VIII Single Chain (rVIII-SingleChain) in Children With Severe Hemophilia A",[90],"2015-08",[403],[1116],{"nctId":1134,"briefTitle":1135,"status":117,"phases":1136,"primaryCompletion":1137,"completion":1137,"start":1138,"enrollment":1139,"conditions":1140,"interventions":1142},"NCT02172950","An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A",[90],"2021-01-19","2014-10-13",246,[21,1141],"Severe Hemophilia A",[1116],{"nctId":1144,"briefTitle":1145,"status":117,"phases":1146,"primaryCompletion":1147,"completion":1147,"start":1052,"enrollment":1148,"conditions":1149,"interventions":1150},"NCT01486927","An Open-label Safety, Efficacy and Pharmacokinetic Study of a Recombinant FVIII Compared to Recombinant Human Antihemophilic FVIII in Patients With Severe Hemophilia A",[89,90],"2014-12",175,[21],[1116,1151],"Octocog alfa",{"trials":1153,"activeCount":99},[],{"trials":1155,"activeCount":99},[],{"intervention":1157,"totalTrials":307,"cells":1158},"Immune globulin subcutaneous",{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1165,"PHASE4":1192,"NA":1194},{"trials":1160,"activeCount":99},[],{"trials":1162,"activeCount":99},[],{"trials":1164,"activeCount":99},[],{"trials":1166,"activeCount":99},[1167,1176,1184],{"nctId":1168,"briefTitle":1169,"status":117,"phases":1170,"primaryCompletion":1028,"completion":155,"start":1171,"enrollment":1172,"conditions":1173,"interventions":1174},"NCT01199705","Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)",[90],"2010-09",25,[26],[1175],"Immune Globulin Subcutaneous",{"nctId":1177,"briefTitle":1178,"status":117,"phases":1179,"primaryCompletion":987,"completion":987,"start":1180,"enrollment":1181,"conditions":1182,"interventions":1183},"NCT01461018","Multicenter Study of Long-Term Clinical Outcomes of Subcutaneous Immune Globulin IgPro20 in Subjects With Primary Immunodeficiency (Japan Study)",[90],"2011-10",22,[26],[1157],{"nctId":1185,"briefTitle":1186,"status":117,"phases":1187,"primaryCompletion":1052,"completion":1188,"start":1019,"enrollment":422,"conditions":1189,"interventions":1191},"NCT01458171","Follow-up Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy (Japan Study)",[90],"2012-04",[1190],"Primary Immune Deficiency Disorder",[1157],{"trials":1193,"activeCount":99},[],{"trials":1195,"activeCount":99},[],{"intervention":1197,"totalTrials":163,"cells":1198},"Fresh frozen plasma",{"EARLY_PHASE1":1199,"PHASE1":1201,"PHASE2":1203,"PHASE3":1205,"PHASE4":1226,"NA":1228},{"trials":1200,"activeCount":99},[],{"trials":1202,"activeCount":99},[],{"trials":1204,"activeCount":99},[],{"trials":1206,"activeCount":99},[1207,1218],{"nctId":1208,"briefTitle":1209,"status":117,"phases":1210,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":1215,"interventions":1216},"NCT00803101","An Open-label, Randomized, Multicenter Phase IIIb Study to Assess the Efficacy, Safety and Tolerance of BERIPLEX® P\u002FN (Kcentra) Compared With Plasma for Rapid Reversal of Coagulopathy Induced by Vitamin K Antagonists in Subjects Requiring an Urgent Surgical Procedure",[90],"2012-11","2013-02","2009-02",176,[327],[1217,1197],"Beriplex® P\u002FN",{"nctId":1219,"briefTitle":1220,"status":117,"phases":1221,"primaryCompletion":1222,"completion":1222,"start":739,"enrollment":1223,"conditions":1224,"interventions":1225},"NCT00708435","Efficacy and Safety Study of BERIPLEX® P\u002FN (Kcentra) Compared With Plasma in Patients With Acute Major Bleeding Caused by Anticoagulant Therapy",[90],"2010-11",216,[872,326],[1217,1197],{"trials":1227,"activeCount":99},[],{"trials":1229,"activeCount":99},[],{"intervention":1231,"totalTrials":163,"cells":1232},"C1 Esterase Inhibitor",{"EARLY_PHASE1":1233,"PHASE1":1235,"PHASE2":1237,"PHASE3":1239,"PHASE4":1260,"NA":1262},{"trials":1234,"activeCount":99},[],{"trials":1236,"activeCount":99},[],{"trials":1238,"activeCount":99},[],{"trials":1240,"activeCount":99},[1241,1251],{"nctId":1242,"briefTitle":1243,"status":117,"phases":1244,"primaryCompletion":1245,"completion":1246,"start":1247,"enrollment":1248,"conditions":1249,"interventions":1250},"NCT00168103","Human C1 Esterase Inhibitor (C1-INH) in Subjects With Acute Abdominal or Facial Hereditary Angioedema (HAE) Attacks",[89,90],"2007-10","2007-12","2005-06",126,[23],[1231],{"nctId":1252,"briefTitle":1253,"status":117,"phases":1254,"primaryCompletion":1255,"completion":1256,"start":1257,"enrollment":9,"conditions":1258,"interventions":1259},"NCT00292981","C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study)",[90],"2010-02","2010-05","2005-08",[23],[1231],{"trials":1261,"activeCount":99},[],{"trials":1263,"activeCount":99},[],{"intervention":1265,"totalTrials":163,"cells":1266},"Clazakizumab",{"EARLY_PHASE1":1267,"PHASE1":1269,"PHASE2":1271,"PHASE3":1284,"PHASE4":1297,"NA":1299},{"trials":1268,"activeCount":99},[],{"trials":1270,"activeCount":99},[],{"trials":1272,"activeCount":99},[1273],{"nctId":1274,"briefTitle":1275,"status":117,"phases":1276,"primaryCompletion":1277,"completion":1278,"start":1279,"enrollment":1280,"conditions":1281,"interventions":1283},"NCT02015520","Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis",[89],"2013-06","2015-06","2012-06",143,[1282],"Rheumatoid Arthritis",[1265],{"trials":1285,"activeCount":99},[1286],{"nctId":1287,"briefTitle":1288,"status":332,"phases":1289,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":1293,"interventions":1295},"NCT03744910","Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients",[90],"2024-04-08","2019-10-14",194,[1294],"Antibody-mediated Rejection",[1265,1296],"Physiologic saline solution",{"trials":1298,"activeCount":99},[],{"trials":1300,"activeCount":99},[],{"intervention":1302,"totalTrials":163,"cells":1303},"Human Normal Immunoglobulin for Subcutaneous Administration",{"EARLY_PHASE1":1304,"PHASE1":1306,"PHASE2":1308,"PHASE3":1310,"PHASE4":1329,"NA":1331},{"trials":1305,"activeCount":99},[],{"trials":1307,"activeCount":99},[],{"trials":1309,"activeCount":99},[],{"trials":1311,"activeCount":99},[1312,1322],{"nctId":1313,"briefTitle":1314,"status":117,"phases":1315,"primaryCompletion":1020,"completion":1020,"start":1316,"enrollment":1317,"conditions":1318,"interventions":1321},"NCT00542997","Study of Subcutaneous Immune Globulin in Patients Requiring IgG Replacement Therapy",[90],"2007-09",51,[28,1319,1320],"X-linked Agammaglobulinemia","Autosomal Recessive Agammaglobulinemia",[1302],{"nctId":1323,"briefTitle":1324,"status":117,"phases":1325,"primaryCompletion":796,"completion":796,"start":1326,"enrollment":765,"conditions":1327,"interventions":1328},"NCT00419341","Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy",[90],"2006-11",[26],[1302],{"trials":1330,"activeCount":99},[],{"trials":1332,"activeCount":99},[],{"intervention":1334,"totalTrials":163,"cells":1335},"CSL689",{"EARLY_PHASE1":1336,"PHASE1":1338,"PHASE2":1352,"PHASE3":1354,"PHASE4":1367,"NA":1369},{"trials":1337,"activeCount":99},[],{"trials":1339,"activeCount":99},[1340],{"nctId":1341,"briefTitle":1342,"status":117,"phases":1343,"primaryCompletion":1344,"completion":1345,"start":1346,"enrollment":1347,"conditions":1348,"interventions":1350},"NCT02470871","Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency",[88],"2016-07","2016-10","2015-07",9,[1349],"Congenital Coagulation Factor VII Deficiency",[1351,1334],"Eptacog alfa (activated) or pdFVII",{"trials":1353,"activeCount":99},[],{"trials":1355,"activeCount":99},[1356],{"nctId":1357,"briefTitle":1358,"status":332,"phases":1359,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1172,"conditions":1362,"interventions":1365},"NCT02484638","Study of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) for On-demand Treatment of Bleeding Episodes in Patients With Hemophilia A or B With Inhibitors",[89,90],"2018-03-28","2015-07-23",[1363,1364],"Hemophilia A With Inhibitors","Hemophilia B With Inhibitors",[1334,1366],"Eptacog alfa",{"trials":1368,"activeCount":99},[],{"trials":1370,"activeCount":99},[],{"intervention":1372,"totalTrials":163,"cells":1373},"C1-esterase inhibitor",{"EARLY_PHASE1":1374,"PHASE1":1376,"PHASE2":1378,"PHASE3":1380,"PHASE4":1398,"NA":1400},{"trials":1375,"activeCount":99},[],{"trials":1377,"activeCount":99},[],{"trials":1379,"activeCount":99},[],{"trials":1381,"activeCount":99},[1382,1390],{"nctId":1383,"briefTitle":1384,"status":117,"phases":1385,"primaryCompletion":1386,"completion":1386,"start":1387,"enrollment":1248,"conditions":1388,"interventions":1389},"NCT02316353","A Study to Evaluate the Long-term Clinical Safety and Efficacy of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema",[90],"2017-09-21","2014-12-31",[31],[1372],{"nctId":1391,"briefTitle":1392,"status":332,"phases":1393,"primaryCompletion":1394,"completion":1394,"start":1395,"enrollment":579,"conditions":1396,"interventions":1397},"NCT03221842","Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant Recipients",[90],"2021-01-20","2017-11-06",[1294],[1372],{"trials":1399,"activeCount":99},[],{"trials":1401,"activeCount":99},[],{"intervention":375,"totalTrials":159,"cells":1403},{"EARLY_PHASE1":1404,"PHASE1":1406,"PHASE2":1408,"PHASE3":1410,"PHASE4":1416,"NA":1418},{"trials":1405,"activeCount":99},[],{"trials":1407,"activeCount":99},[],{"trials":1409,"activeCount":99},[],{"trials":1411,"activeCount":99},[1412],{"nctId":365,"briefTitle":366,"status":107,"phases":1413,"primaryCompletion":368,"completion":368,"start":369,"enrollment":99,"conditions":1414,"interventions":1415},[90],[371,372,373],[375,354],{"trials":1417,"activeCount":99},[],{"trials":1419,"activeCount":99},[],{"intervention":1421,"totalTrials":159,"cells":1422},"Apolipoprotein A-I [human]",{"EARLY_PHASE1":1423,"PHASE1":1425,"PHASE2":1427,"PHASE3":1429,"PHASE4":1442,"NA":1444},{"trials":1424,"activeCount":99},[],{"trials":1426,"activeCount":99},[],{"trials":1428,"activeCount":99},[],{"trials":1430,"activeCount":99},[1431],{"nctId":1432,"briefTitle":1433,"status":117,"phases":1434,"primaryCompletion":1435,"completion":1436,"start":1437,"enrollment":1438,"conditions":1439,"interventions":1441},"NCT03473223","Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome",[90],"2023-02-16","2023-11-17","2018-03-21",18226,[1440],"Acute Coronary Syndrome",[1421],{"trials":1443,"activeCount":99},[],{"trials":1445,"activeCount":99},[],{"intervention":1447,"totalTrials":159,"cells":1448},"10% liquid formulation of human immunoglobulin",{"EARLY_PHASE1":1449,"PHASE1":1451,"PHASE2":1453,"PHASE3":1455,"PHASE4":1464,"NA":1466},{"trials":1450,"activeCount":99},[],{"trials":1452,"activeCount":99},[],{"trials":1454,"activeCount":99},[],{"trials":1456,"activeCount":99},[1457],{"nctId":1458,"briefTitle":1459,"status":117,"phases":1460,"primaryCompletion":155,"completion":155,"start":1222,"enrollment":1461,"conditions":1462,"interventions":1463},"NCT01184846","Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy",[90],31,[33],[1447],{"trials":1465,"activeCount":99},[],{"trials":1467,"activeCount":99},[],{"intervention":1296,"totalTrials":159,"cells":1469},{"EARLY_PHASE1":1470,"PHASE1":1472,"PHASE2":1474,"PHASE3":1476,"PHASE4":1482,"NA":1484},{"trials":1471,"activeCount":99},[],{"trials":1473,"activeCount":99},[],{"trials":1475,"activeCount":99},[],{"trials":1477,"activeCount":99},[1478],{"nctId":1287,"briefTitle":1288,"status":332,"phases":1479,"primaryCompletion":1290,"completion":1290,"start":1291,"enrollment":1292,"conditions":1480,"interventions":1481},[90],[1294],[1265,1296],{"trials":1483,"activeCount":99},[],{"trials":1485,"activeCount":99},[],{"intervention":1487,"totalTrials":159,"cells":1488},"Fibrinogen Concentrate",{"EARLY_PHASE1":1489,"PHASE1":1491,"PHASE2":1493,"PHASE3":1495,"PHASE4":1507,"NA":1509},{"trials":1490,"activeCount":99},[],{"trials":1492,"activeCount":99},[],{"trials":1494,"activeCount":99},[],{"trials":1496,"activeCount":99},[1497],{"nctId":1498,"briefTitle":1499,"status":117,"phases":1500,"primaryCompletion":987,"completion":154,"start":1501,"enrollment":1502,"conditions":1503,"interventions":1506},"NCT01475669","Study of Fibrinogen Concentrate (Human) (FCH) to Control Bleeding During Complex Cardiovascular Surgery",[90],"2012-01",152,[1504,1505],"Surgical Blood Loss","Postoperative Blood Loss",[1487],{"trials":1508,"activeCount":99},[],{"trials":1510,"activeCount":99},[],{"intervention":1512,"totalTrials":159,"cells":1513},"AAT",{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1520,"PHASE4":1532,"NA":1534},{"trials":1515,"activeCount":99},[],{"trials":1517,"activeCount":99},[],{"trials":1519,"activeCount":99},[],{"trials":1521,"activeCount":99},[1522],{"nctId":1523,"briefTitle":1524,"status":117,"phases":1525,"primaryCompletion":1526,"completion":1526,"start":1527,"enrollment":1528,"conditions":1529,"interventions":1531},"NCT03805789","The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant",[89,90],"2026-03-19","2019-03-27",222,[1530],"Acute-graft-versus-host Disease",[1512],{"trials":1533,"activeCount":99},[],{"trials":1535,"activeCount":99},[],{"intervention":1537,"totalTrials":159,"cells":1538},"Low-volume C1-esterase inhibitor",{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1545,"PHASE4":1558,"NA":1560},{"trials":1540,"activeCount":99},[],{"trials":1542,"activeCount":99},[],{"trials":1544,"activeCount":99},[],{"trials":1546,"activeCount":99},[1547],{"nctId":1548,"briefTitle":1549,"status":117,"phases":1550,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":380,"conditions":1553,"interventions":1554},"NCT01912456","A Study to Evaluate the Clinical Efficacy and Safety of Subcutaneously Administered C1-esterase Inhibitor in the Prevention of Hereditary Angioedema",[90],"2015-10","2014-01",[31],[1537,1555,1556,1557],"Higher-volume C1-esterase inhibitor","Low-volume placebo","Higher-volume placebo",{"trials":1559,"activeCount":99},[],{"trials":1561,"activeCount":99},[],{"intervention":1555,"totalTrials":159,"cells":1563},{"EARLY_PHASE1":1564,"PHASE1":1566,"PHASE2":1568,"PHASE3":1570,"PHASE4":1576,"NA":1578},{"trials":1565,"activeCount":99},[],{"trials":1567,"activeCount":99},[],{"trials":1569,"activeCount":99},[],{"trials":1571,"activeCount":99},[1572],{"nctId":1548,"briefTitle":1549,"status":117,"phases":1573,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":380,"conditions":1574,"interventions":1575},[90],[31],[1537,1555,1556,1557],{"trials":1577,"activeCount":99},[],{"trials":1579,"activeCount":99},[],{"intervention":1556,"totalTrials":159,"cells":1581},{"EARLY_PHASE1":1582,"PHASE1":1584,"PHASE2":1586,"PHASE3":1588,"PHASE4":1594,"NA":1596},{"trials":1583,"activeCount":99},[],{"trials":1585,"activeCount":99},[],{"trials":1587,"activeCount":99},[],{"trials":1589,"activeCount":99},[1590],{"nctId":1548,"briefTitle":1549,"status":117,"phases":1591,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":380,"conditions":1592,"interventions":1593},[90],[31],[1537,1555,1556,1557],{"trials":1595,"activeCount":99},[],{"trials":1597,"activeCount":99},[],{"intervention":1557,"totalTrials":159,"cells":1599},{"EARLY_PHASE1":1600,"PHASE1":1602,"PHASE2":1604,"PHASE3":1606,"PHASE4":1612,"NA":1614},{"trials":1601,"activeCount":99},[],{"trials":1603,"activeCount":99},[],{"trials":1605,"activeCount":99},[],{"trials":1607,"activeCount":99},[1608],{"nctId":1548,"briefTitle":1549,"status":117,"phases":1609,"primaryCompletion":1551,"completion":1551,"start":1552,"enrollment":380,"conditions":1610,"interventions":1611},[90],[31],[1537,1555,1556,1557],{"trials":1613,"activeCount":99},[],{"trials":1615,"activeCount":99},[],{"intervention":1617,"totalTrials":159,"cells":1618},"Biostate®",{"EARLY_PHASE1":1619,"PHASE1":1621,"PHASE2":1623,"PHASE3":1625,"PHASE4":1634,"NA":1636},{"trials":1620,"activeCount":99},[],{"trials":1622,"activeCount":99},[],{"trials":1624,"activeCount":99},[],{"trials":1626,"activeCount":99},[1627],{"nctId":1628,"briefTitle":1629,"status":117,"phases":1630,"primaryCompletion":1052,"completion":1052,"start":1631,"enrollment":1181,"conditions":1632,"interventions":1633},"NCT00941616","Study of a pd VWF\u002FFVIII Concentrate, Biostate®, in Subjects With Von Willebrand Disease",[89,90],"2009-06",[18],[1617,1617],{"trials":1635,"activeCount":99},[],{"trials":1637,"activeCount":99},[],{"intervention":1366,"totalTrials":159,"cells":1639},{"EARLY_PHASE1":1640,"PHASE1":1642,"PHASE2":1644,"PHASE3":1646,"PHASE4":1652,"NA":1654},{"trials":1641,"activeCount":99},[],{"trials":1643,"activeCount":99},[],{"trials":1645,"activeCount":99},[],{"trials":1647,"activeCount":99},[1648],{"nctId":1357,"briefTitle":1358,"status":332,"phases":1649,"primaryCompletion":1360,"completion":1360,"start":1361,"enrollment":1172,"conditions":1650,"interventions":1651},[89,90],[1363,1364],[1334,1366],{"trials":1653,"activeCount":99},[],{"trials":1655,"activeCount":99},[],{"intervention":1657,"totalTrials":159,"cells":1658},"Immunoglobulin Intravenous",{"EARLY_PHASE1":1659,"PHASE1":1661,"PHASE2":1663,"PHASE3":1665,"PHASE4":1676,"NA":1678},{"trials":1660,"activeCount":99},[],{"trials":1662,"activeCount":99},[],{"trials":1664,"activeCount":99},[],{"trials":1666,"activeCount":99},[1667],{"nctId":1668,"briefTitle":1669,"status":117,"phases":1670,"completion":1671,"start":1672,"enrollment":1673,"conditions":1674,"interventions":1675},"NCT00168038","Treatment of Chronic Immune Thrombocytopenic Purpura (ITP) With Intravenous Immunoglobulin IgPro10",[90],"2006-02","2004-12",58,[157],[1657],{"trials":1677,"activeCount":99},[],{"trials":1679,"activeCount":99},[],{"intervention":1681,"totalTrials":159,"cells":1682},"Alpha-1 antitrypsin",{"EARLY_PHASE1":1683,"PHASE1":1685,"PHASE2":1687,"PHASE3":1689,"PHASE4":1702,"NA":1704},{"trials":1684,"activeCount":99},[],{"trials":1686,"activeCount":99},[],{"trials":1688,"activeCount":99},[],{"trials":1690,"activeCount":99},[1691],{"nctId":1692,"briefTitle":1693,"status":117,"phases":1694,"primaryCompletion":1695,"completion":1696,"start":1697,"enrollment":1698,"conditions":1699,"interventions":1701},"NCT04167514","Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone",[90],"2023-09-11","2024-06-26","2020-01-09",136,[1700],"Graft Versus Host Disease (GVHD)",[1681],{"trials":1703,"activeCount":99},[],{"trials":1705,"activeCount":99},[],{"intervention":1707,"totalTrials":159,"cells":1708},"human immunoglobulin G",{"EARLY_PHASE1":1709,"PHASE1":1711,"PHASE2":1713,"PHASE3":1715,"PHASE4":1727,"NA":1729},{"trials":1710,"activeCount":99},[],{"trials":1712,"activeCount":99},[],{"trials":1714,"activeCount":99},[],{"trials":1716,"activeCount":99},[1717],{"nctId":1718,"briefTitle":1719,"status":332,"phases":1720,"primaryCompletion":1721,"completion":1721,"start":1722,"enrollment":1723,"conditions":1724,"interventions":1726},"NCT04044690","A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM)",[90],"2024-12-02","2019-10-21",134,[1725],"Dermatomyositis",[1707],{"trials":1728,"activeCount":99},[],{"trials":1730,"activeCount":99},[],{"intervention":1151,"totalTrials":159,"cells":1732},{"EARLY_PHASE1":1733,"PHASE1":1735,"PHASE2":1737,"PHASE3":1739,"PHASE4":1745,"NA":1747},{"trials":1734,"activeCount":99},[],{"trials":1736,"activeCount":99},[],{"trials":1738,"activeCount":99},[],{"trials":1740,"activeCount":99},[1741],{"nctId":1144,"briefTitle":1145,"status":117,"phases":1742,"primaryCompletion":1147,"completion":1147,"start":1052,"enrollment":1148,"conditions":1743,"interventions":1744},[89,90],[21],[1116,1151],{"trials":1746,"activeCount":99},[],{"trials":1748,"activeCount":99},[],{"intervention":1750,"totalTrials":159,"cells":1751},"Prothrombin Complex Concentrate",{"EARLY_PHASE1":1752,"PHASE1":1754,"PHASE2":1756,"PHASE3":1758,"PHASE4":1767,"NA":1769},{"trials":1753,"activeCount":99},[],{"trials":1755,"activeCount":99},[],{"trials":1757,"activeCount":99},[],{"trials":1759,"activeCount":99},[1760],{"nctId":1761,"briefTitle":1762,"status":117,"phases":1763,"completion":1326,"start":1099,"enrollment":719,"conditions":1764,"interventions":1766},"NCT00168077","Prothrombin Complex Concentrate for Anticoagulant Reversal",[90],[1765],"Acquired Coagulation Factor Deficiency",[1750],{"trials":1768,"activeCount":99},[],{"trials":1770,"activeCount":99},[],{"intervention":1772,"totalTrials":34,"cells":1773},"ALD518",{"EARLY_PHASE1":1774,"PHASE1":1776,"PHASE2":1778,"PHASE3":1821,"PHASE4":1823,"NA":1825},{"trials":1775,"activeCount":99},[],{"trials":1777,"activeCount":99},[],{"trials":1779,"activeCount":99},[1780,1788,1799,1812],{"nctId":1781,"briefTitle":1782,"status":332,"phases":1783,"primaryCompletion":1784,"completion":1784,"start":132,"enrollment":307,"conditions":1785,"interventions":1787},"NCT01530256","Exploratory Safety Study of ALD518 in Subjects With Steroid-refractory Acute Graft Versus Host Disease (GVHD)",[88,89],"2013-03",[1786],"Acute GvHD",[1772,1772,1772],{"nctId":1789,"briefTitle":1790,"status":332,"phases":1791,"primaryCompletion":1792,"completion":368,"start":1793,"enrollment":1794,"conditions":1795,"interventions":1797},"NCT01403064","Safety and Efficacy of ALD518 for Reducing Oral Mucositis in Head and Neck Cancer Subjects",[89],"2013-04","2011-07",76,[1796],"Oral Mucositis",[1772,1798],"0.9% saline",{"nctId":1800,"briefTitle":1801,"status":117,"phases":1802,"primaryCompletion":1020,"completion":1803,"start":1804,"enrollment":1805,"conditions":1806,"interventions":1810},"NCT00866970","Safety, Efficacy and Pharmacokinetics of ALD518 in Patients With Non-Small Cell Lung Cancer-related Fatigue and Cachexia",[89],"2009-12","2008-09",124,[1807,1808,1809],"NSCLC","Fatigue","Cachexia",[1772,1772,1772,1811],"Infusion of 0.9% Saline without ALD518",{"nctId":1813,"briefTitle":1814,"status":117,"phases":1815,"primaryCompletion":1631,"completion":1803,"start":796,"enrollment":1816,"conditions":1817,"interventions":1819},"NCT00867516","Safety, Efficacy and Pharmacokinetics Study of ALD518 in Patients With Active Rheumatoid Arthritis",[89],127,[1818],"Arthritis, Rheumatoid",[1772,1820],"Infusion without ALD518'",{"trials":1822,"activeCount":99},[],{"trials":1824,"activeCount":99},[],{"trials":1826,"activeCount":99},[],{"intervention":1828,"totalTrials":307,"cells":1829},"BMS-945429",{"EARLY_PHASE1":1830,"PHASE1":1832,"PHASE2":1834,"PHASE3":1865,"PHASE4":1867,"NA":1869},{"trials":1831,"activeCount":99},[],{"trials":1833,"activeCount":99},[],{"trials":1835,"activeCount":99},[1836,1844,1852],{"nctId":1837,"briefTitle":1838,"status":117,"phases":1839,"primaryCompletion":1277,"completion":1278,"start":717,"enrollment":1840,"conditions":1841,"interventions":1843},"NCT01490450","Psoriatic Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to NSAIDs or Non-biologic Disease Modifying Anti-rheumatic Drugs (DMARDs) Therapy",[89],165,[1842],"Arthritis, Psoriatic",[1828,1828,1828],{"nctId":1845,"briefTitle":1846,"status":332,"phases":1847,"primaryCompletion":970,"completion":970,"start":1279,"enrollment":1848,"conditions":1849,"interventions":1851},"NCT01545050","Dose Ranging Study of BMS-945429 in Subjects With Moderate to Severe Crohn's Disease",[89],72,[1850],"Crohn's Disease",[1828,1828,1828,1828,1828,1828,1828,1828,1828],{"nctId":1853,"briefTitle":1854,"status":117,"phases":1855,"primaryCompletion":820,"completion":1278,"start":1856,"enrollment":1857,"conditions":1858,"interventions":1859},"NCT01373151","Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate",[89],"2011-06",418,[1282],[1860,1828,1828,1828,1828,1861,1861,1862,1861,1863,1864],"BMS-945429 Placebo","Methotrexate","Methotrexate Placebo","Adalimumab Placebo","Adalimumab",{"trials":1866,"activeCount":99},[],{"trials":1868,"activeCount":99},[],{"trials":1870,"activeCount":99},[],{"intervention":1872,"totalTrials":307,"cells":1873},"CSL324",{"EARLY_PHASE1":1874,"PHASE1":1876,"PHASE2":1897,"PHASE3":1909,"PHASE4":1911,"NA":1913},{"trials":1875,"activeCount":99},[],{"trials":1877,"activeCount":99},[1878,1889],{"nctId":1879,"briefTitle":1880,"status":117,"phases":1881,"primaryCompletion":1882,"completion":1883,"start":1884,"enrollment":1885,"conditions":1886,"interventions":1888},"NCT04570267","Pharmacokinetics and Safety of Subcutaneous CSL324 in Healthy Japanese and White Subjects",[88],"2021-11-17","2021-12-09","2020-10-08",32,[1887],"Healthy",[1872],{"nctId":1890,"briefTitle":1891,"status":117,"phases":1892,"primaryCompletion":1893,"completion":1893,"start":1894,"enrollment":719,"conditions":1895,"interventions":1896},"NCT05653713","Effects of CSL324 in the Lung After Segmental Challenge",[88],"2023-07-21","2022-12-20",[513],[1872],{"trials":1898,"activeCount":99},[1899],{"nctId":1900,"briefTitle":1901,"status":107,"phases":1902,"primaryCompletion":1903,"completion":1904,"start":1905,"enrollment":99,"conditions":1906,"interventions":1908},"NCT04519424","CSL324 in COVID-19",[89],"2021-04","2021-05","2020-09",[1907],"Coronavirus Disease 2019 (COVID-19)",[1872],{"trials":1910,"activeCount":99},[],{"trials":1912,"activeCount":99},[],{"trials":1914,"activeCount":99},[],{"intervention":1916,"totalTrials":163,"cells":1917},"CSL112",{"EARLY_PHASE1":1918,"PHASE1":1920,"PHASE2":1932,"PHASE3":1943,"PHASE4":1945,"NA":1947},{"trials":1919,"activeCount":99},[],{"trials":1921,"activeCount":99},[1922],{"nctId":1923,"briefTitle":1924,"status":117,"phases":1925,"primaryCompletion":1926,"completion":1927,"start":1928,"enrollment":1885,"conditions":1929,"interventions":1931},"NCT02427035","A Study of CSL112 in Healthy Adults and in Adults With Moderate Renal Impairment",[88],"2015-11","2016-02","2015-05",[1930],"Acute Myocardial Infarction",[1916],{"trials":1933,"activeCount":99},[1934],{"nctId":1935,"briefTitle":1936,"status":117,"phases":1937,"primaryCompletion":1938,"completion":322,"start":1939,"enrollment":1940,"conditions":1941,"interventions":1942},"NCT02108262","A Phase 2b Study of CSL112 in Subjects With Acute Myocardial Infarction.",[89],"2015-12","2014-08",1267,[1930],[1916],{"trials":1944,"activeCount":99},[],{"trials":1946,"activeCount":99},[],{"trials":1948,"activeCount":99},[],{"intervention":1950,"totalTrials":163,"cells":1951},"Recombinant Coagulation Factor IX Albumin Fusion Protein",{"EARLY_PHASE1":1952,"PHASE1":1954,"PHASE2":1963,"PHASE3":1972,"PHASE4":1974,"NA":1976},{"trials":1953,"activeCount":99},[],{"trials":1955,"activeCount":99},[1956],{"nctId":1957,"briefTitle":1958,"status":117,"phases":1959,"primaryCompletion":1793,"completion":1793,"start":963,"enrollment":1172,"conditions":1960,"interventions":1961},"NCT01233440","Safety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia B",[88],[15],[1950,1962],"Plasma derived FIX [pdFIX]",{"trials":1964,"activeCount":99},[1965],{"nctId":1966,"briefTitle":1967,"status":117,"phases":1968,"primaryCompletion":1279,"completion":1969,"start":1793,"enrollment":980,"conditions":1970,"interventions":1971},"NCT01361126","A Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia B",[88,89],"2012-07",[15],[1950],{"trials":1973,"activeCount":99},[],{"trials":1975,"activeCount":99},[],{"trials":1977,"activeCount":99},[],{"intervention":1979,"totalTrials":159,"cells":1980},"CSL346",{"EARLY_PHASE1":1981,"PHASE1":1983,"PHASE2":1985,"PHASE3":1997,"PHASE4":1999,"NA":2001},{"trials":1982,"activeCount":99},[],{"trials":1984,"activeCount":99},[],{"trials":1986,"activeCount":99},[1987],{"nctId":1988,"briefTitle":1989,"status":117,"phases":1990,"primaryCompletion":1991,"completion":1991,"start":1992,"enrollment":1993,"conditions":1994,"interventions":1996},"NCT04419467","Vascular Endothelial Growth Factor-B (VEGF-B) Blockade With the Monoclonal Antibody CSL346 in Subjects With Diabetic Kidney Disease",[89],"2022-10-24","2020-09-14",114,[1995],"Diabetic Kidney Disease (DKD)",[1979],{"trials":1998,"activeCount":99},[],{"trials":2000,"activeCount":99},[],{"trials":2002,"activeCount":99},[],{"intervention":2004,"totalTrials":159,"cells":2005},"Garadacimab, Factor XIIa Antagonist Monoclonal Antibody",{"EARLY_PHASE1":2006,"PHASE1":2008,"PHASE2":2010,"PHASE3":2020,"PHASE4":2022,"NA":2024},{"trials":2007,"activeCount":99},[],{"trials":2009,"activeCount":99},[],{"trials":2011,"activeCount":99},[2012],{"nctId":2013,"briefTitle":2014,"status":117,"phases":2015,"primaryCompletion":2016,"completion":2016,"start":2017,"enrollment":1805,"conditions":2018,"interventions":2019},"NCT04409509","Treatment With CSL312 in Adults With Coronavirus Disease 2019 (COVID-19)",[89],"2021-01-12","2020-07-01",[1907],[2004],{"trials":2021,"activeCount":99},[],{"trials":2023,"activeCount":99},[],{"trials":2025,"activeCount":99},[],{"intervention":2027,"totalTrials":159,"cells":2028},"CSL_112",{"EARLY_PHASE1":2029,"PHASE1":2031,"PHASE2":2033,"PHASE3":2045,"PHASE4":2047,"NA":2049},{"trials":2030,"activeCount":99},[],{"trials":2032,"activeCount":99},[],{"trials":2034,"activeCount":99},[2035],{"nctId":2036,"briefTitle":2037,"status":117,"phases":2038,"primaryCompletion":2039,"completion":2039,"start":2040,"enrollment":2041,"conditions":2042,"interventions":2044},"NCT02742103","A Study of CSL112 in Adults With Moderate Renal Impairment and Acute Myocardial Infarction",[89],"2017-06","2016-08",83,[1930,2043],"Moderate Renal Impairment",[2027],{"trials":2046,"activeCount":99},[],{"trials":2048,"activeCount":99},[],{"trials":2050,"activeCount":99},[],{"intervention":2052,"totalTrials":159,"cells":2053},"C1-esterase inhibitor - single intravenous dose",{"EARLY_PHASE1":2054,"PHASE1":2056,"PHASE2":2058,"PHASE3":2069,"PHASE4":2071,"NA":2073},{"trials":2055,"activeCount":99},[],{"trials":2057,"activeCount":99},[],{"trials":2059,"activeCount":99},[2060],{"nctId":2061,"briefTitle":2062,"status":117,"phases":2063,"primaryCompletion":971,"completion":971,"start":1188,"enrollment":189,"conditions":2064,"interventions":2065},"NCT01576523","A Study to Evaluate the Clinical Pharmacology and Safety of C1-esterase Inhibitor Administered by the Subcutaneous Route",[88,89],[31],[2052,2066,2067,2068],"C1-esterase inhibitor - subcutaneous low dose","C1-esterase inhibitor - subcutaneous medium dose","C1-esterase inhibitor - subcutaneous high dose",{"trials":2070,"activeCount":99},[],{"trials":2072,"activeCount":99},[],{"trials":2074,"activeCount":99},[],{"intervention":2066,"totalTrials":159,"cells":2076},{"EARLY_PHASE1":2077,"PHASE1":2079,"PHASE2":2081,"PHASE3":2087,"PHASE4":2089,"NA":2091},{"trials":2078,"activeCount":99},[],{"trials":2080,"activeCount":99},[],{"trials":2082,"activeCount":99},[2083],{"nctId":2061,"briefTitle":2062,"status":117,"phases":2084,"primaryCompletion":971,"completion":971,"start":1188,"enrollment":189,"conditions":2085,"interventions":2086},[88,89],[31],[2052,2066,2067,2068],{"trials":2088,"activeCount":99},[],{"trials":2090,"activeCount":99},[],{"trials":2092,"activeCount":99},[],{"intervention":2067,"totalTrials":159,"cells":2094},{"EARLY_PHASE1":2095,"PHASE1":2097,"PHASE2":2099,"PHASE3":2105,"PHASE4":2107,"NA":2109},{"trials":2096,"activeCount":99},[],{"trials":2098,"activeCount":99},[],{"trials":2100,"activeCount":99},[2101],{"nctId":2061,"briefTitle":2062,"status":117,"phases":2102,"primaryCompletion":971,"completion":971,"start":1188,"enrollment":189,"conditions":2103,"interventions":2104},[88,89],[31],[2052,2066,2067,2068],{"trials":2106,"activeCount":99},[],{"trials":2108,"activeCount":99},[],{"trials":2110,"activeCount":99},[],{"intervention":2068,"totalTrials":159,"cells":2112},{"EARLY_PHASE1":2113,"PHASE1":2115,"PHASE2":2117,"PHASE3":2123,"PHASE4":2125,"NA":2127},{"trials":2114,"activeCount":99},[],{"trials":2116,"activeCount":99},[],{"trials":2118,"activeCount":99},[2119],{"nctId":2061,"briefTitle":2062,"status":117,"phases":2120,"primaryCompletion":971,"completion":971,"start":1188,"enrollment":189,"conditions":2121,"interventions":2122},[88,89],[31],[2052,2066,2067,2068],{"trials":2124,"activeCount":99},[],{"trials":2126,"activeCount":99},[],{"trials":2128,"activeCount":99},[],{"intervention":2130,"totalTrials":159,"cells":2131},"Human Fibrinogen Concentrate",{"EARLY_PHASE1":2132,"PHASE1":2134,"PHASE2":2136,"PHASE3":2146,"PHASE4":2148,"NA":2150},{"trials":2133,"activeCount":99},[],{"trials":2135,"activeCount":99},[],{"trials":2137,"activeCount":99},[2138],{"nctId":2139,"briefTitle":2140,"status":117,"phases":2141,"primaryCompletion":2142,"completion":2142,"start":2143,"enrollment":1009,"conditions":2144,"interventions":2145},"NCT00496262","Human Fibrinogen - Pharmacokinetics",[89],"2008-05","2007-07",[373],[2130],{"trials":2147,"activeCount":99},[],{"trials":2149,"activeCount":99},[],{"trials":2151,"activeCount":99},[],{"intervention":2153,"totalTrials":159,"cells":2154},"Factor XIIa antagonist monoclonal antibody",{"EARLY_PHASE1":2155,"PHASE1":2157,"PHASE2":2159,"PHASE3":2170,"PHASE4":2172,"NA":2174},{"trials":2156,"activeCount":99},[],{"trials":2158,"activeCount":99},[],{"trials":2160,"activeCount":99},[2161],{"nctId":2162,"briefTitle":2163,"status":117,"phases":2164,"primaryCompletion":2165,"completion":2165,"start":2166,"enrollment":2167,"conditions":2168,"interventions":2169},"NCT03712228","A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)",[89],"2021-10-15","2018-10-29",44,[23],[2153],{"trials":2171,"activeCount":99},[],{"trials":2173,"activeCount":99},[],{"trials":2175,"activeCount":99},[],{"intervention":2177,"totalTrials":159,"cells":2178},"Haemocomplettan® P",{"EARLY_PHASE1":2179,"PHASE1":2181,"PHASE2":2183,"PHASE3":2195,"PHASE4":2197,"NA":2199},{"trials":2180,"activeCount":99},[],{"trials":2182,"activeCount":99},[],{"trials":2184,"activeCount":99},[2185],{"nctId":2186,"briefTitle":2187,"status":117,"phases":2188,"primaryCompletion":2189,"completion":1007,"start":739,"enrollment":2190,"conditions":2191,"interventions":2193},"NCT00701142","Haemocomplettan® P During Aortic Replacement",[89],"2010-03",80,[2192],"Aortic Aneurysm",[2177,2194],"Saline solution",{"trials":2196,"activeCount":99},[],{"trials":2198,"activeCount":99},[],{"trials":2200,"activeCount":99},[],{"intervention":2194,"totalTrials":159,"cells":2202},{"EARLY_PHASE1":2203,"PHASE1":2205,"PHASE2":2207,"PHASE3":2213,"PHASE4":2215,"NA":2217},{"trials":2204,"activeCount":99},[],{"trials":2206,"activeCount":99},[],{"trials":2208,"activeCount":99},[2209],{"nctId":2186,"briefTitle":2187,"status":117,"phases":2210,"primaryCompletion":2189,"completion":1007,"start":739,"enrollment":2190,"conditions":2211,"interventions":2212},[89],[2192],[2177,2194],{"trials":2214,"activeCount":99},[],{"trials":2216,"activeCount":99},[],{"trials":2218,"activeCount":99},[],{"intervention":1798,"totalTrials":159,"cells":2220},{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2231,"PHASE4":2233,"NA":2235},{"trials":2222,"activeCount":99},[],{"trials":2224,"activeCount":99},[],{"trials":2226,"activeCount":99},[2227],{"nctId":1789,"briefTitle":1790,"status":332,"phases":2228,"primaryCompletion":1792,"completion":368,"start":1793,"enrollment":1794,"conditions":2229,"interventions":2230},[89],[1796],[1772,1798],{"trials":2232,"activeCount":99},[],{"trials":2234,"activeCount":99},[],{"trials":2236,"activeCount":99},[],{"intervention":1811,"totalTrials":159,"cells":2238},{"EARLY_PHASE1":2239,"PHASE1":2241,"PHASE2":2243,"PHASE3":2249,"PHASE4":2251,"NA":2253},{"trials":2240,"activeCount":99},[],{"trials":2242,"activeCount":99},[],{"trials":2244,"activeCount":99},[2245],{"nctId":1800,"briefTitle":1801,"status":117,"phases":2246,"primaryCompletion":1020,"completion":1803,"start":1804,"enrollment":1805,"conditions":2247,"interventions":2248},[89],[1807,1808,1809],[1772,1772,1772,1811],{"trials":2250,"activeCount":99},[],{"trials":2252,"activeCount":99},[],{"trials":2254,"activeCount":99},[],{"intervention":1820,"totalTrials":159,"cells":2256},{"EARLY_PHASE1":2257,"PHASE1":2259,"PHASE2":2261,"PHASE3":2267,"PHASE4":2269,"NA":2271},{"trials":2258,"activeCount":99},[],{"trials":2260,"activeCount":99},[],{"trials":2262,"activeCount":99},[2263],{"nctId":1813,"briefTitle":1814,"status":117,"phases":2264,"primaryCompletion":1631,"completion":1803,"start":796,"enrollment":1816,"conditions":2265,"interventions":2266},[89],[1818],[1772,1820],{"trials":2268,"activeCount":99},[],{"trials":2270,"activeCount":99},[],{"trials":2272,"activeCount":99},[],{"intervention":2274,"totalTrials":159,"cells":2275},"Biostate® [SP]",{"EARLY_PHASE1":2276,"PHASE1":2278,"PHASE2":2280,"PHASE3":2289,"PHASE4":2291,"NA":2293},{"trials":2277,"activeCount":99},[],{"trials":2279,"activeCount":99},[],{"trials":2281,"activeCount":99},[2282],{"nctId":2283,"briefTitle":2284,"status":117,"phases":2285,"primaryCompletion":963,"completion":963,"start":1213,"enrollment":177,"conditions":2286,"interventions":2287},"NCT00879541","Study of a pd vWF\u002FFVIII, Biostate®, in Subjects With Haemophilia A",[89],[21],[2274,2274,2288],"Biostate® [RP]",{"trials":2290,"activeCount":99},[],{"trials":2292,"activeCount":99},[],{"trials":2294,"activeCount":99},[],{"intervention":2288,"totalTrials":159,"cells":2296},{"EARLY_PHASE1":2297,"PHASE1":2299,"PHASE2":2301,"PHASE3":2307,"PHASE4":2309,"NA":2311},{"trials":2298,"activeCount":99},[],{"trials":2300,"activeCount":99},[],{"trials":2302,"activeCount":99},[2303],{"nctId":2283,"briefTitle":2284,"status":117,"phases":2304,"primaryCompletion":963,"completion":963,"start":1213,"enrollment":177,"conditions":2305,"interventions":2306},[89],[21],[2274,2274,2288],{"trials":2308,"activeCount":99},[],{"trials":2310,"activeCount":99},[],{"trials":2312,"activeCount":99},[],{"intervention":1860,"totalTrials":159,"cells":2314},{"EARLY_PHASE1":2315,"PHASE1":2317,"PHASE2":2319,"PHASE3":2325,"PHASE4":2327,"NA":2329},{"trials":2316,"activeCount":99},[],{"trials":2318,"activeCount":99},[],{"trials":2320,"activeCount":99},[2321],{"nctId":1853,"briefTitle":1854,"status":117,"phases":2322,"primaryCompletion":820,"completion":1278,"start":1856,"enrollment":1857,"conditions":2323,"interventions":2324},[89],[1282],[1860,1828,1828,1828,1828,1861,1861,1862,1861,1863,1864],{"trials":2326,"activeCount":99},[],{"trials":2328,"activeCount":99},[],{"trials":2330,"activeCount":99},[],{"intervention":1861,"totalTrials":159,"cells":2332},{"EARLY_PHASE1":2333,"PHASE1":2335,"PHASE2":2337,"PHASE3":2343,"PHASE4":2345,"NA":2347},{"trials":2334,"activeCount":99},[],{"trials":2336,"activeCount":99},[],{"trials":2338,"activeCount":99},[2339],{"nctId":1853,"briefTitle":1854,"status":117,"phases":2340,"primaryCompletion":820,"completion":1278,"start":1856,"enrollment":1857,"conditions":2341,"interventions":2342},[89],[1282],[1860,1828,1828,1828,1828,1861,1861,1862,1861,1863,1864],{"trials":2344,"activeCount":99},[],{"trials":2346,"activeCount":99},[],{"trials":2348,"activeCount":99},[],{"intervention":1862,"totalTrials":159,"cells":2350},{"EARLY_PHASE1":2351,"PHASE1":2353,"PHASE2":2355,"PHASE3":2361,"PHASE4":2363,"NA":2365},{"trials":2352,"activeCount":99},[],{"trials":2354,"activeCount":99},[],{"trials":2356,"activeCount":99},[2357],{"nctId":1853,"briefTitle":1854,"status":117,"phases":2358,"primaryCompletion":820,"completion":1278,"start":1856,"enrollment":1857,"conditions":2359,"interventions":2360},[89],[1282],[1860,1828,1828,1828,1828,1861,1861,1862,1861,1863,1864],{"trials":2362,"activeCount":99},[],{"trials":2364,"activeCount":99},[],{"trials":2366,"activeCount":99},[],{"intervention":1863,"totalTrials":159,"cells":2368},{"EARLY_PHASE1":2369,"PHASE1":2371,"PHASE2":2373,"PHASE3":2379,"PHASE4":2381,"NA":2383},{"trials":2370,"activeCount":99},[],{"trials":2372,"activeCount":99},[],{"trials":2374,"activeCount":99},[2375],{"nctId":1853,"briefTitle":1854,"status":117,"phases":2376,"primaryCompletion":820,"completion":1278,"start":1856,"enrollment":1857,"conditions":2377,"interventions":2378},[89],[1282],[1860,1828,1828,1828,1828,1861,1861,1862,1861,1863,1864],{"trials":2380,"activeCount":99},[],{"trials":2382,"activeCount":99},[],{"trials":2384,"activeCount":99},[],{"intervention":1864,"totalTrials":159,"cells":2386},{"EARLY_PHASE1":2387,"PHASE1":2389,"PHASE2":2391,"PHASE3":2397,"PHASE4":2399,"NA":2401},{"trials":2388,"activeCount":99},[],{"trials":2390,"activeCount":99},[],{"trials":2392,"activeCount":99},[2393],{"nctId":1853,"briefTitle":1854,"status":117,"phases":2394,"primaryCompletion":820,"completion":1278,"start":1856,"enrollment":1857,"conditions":2395,"interventions":2396},[89],[1282],[1860,1828,1828,1828,1828,1861,1861,1862,1861,1863,1864],{"trials":2398,"activeCount":99},[],{"trials":2400,"activeCount":99},[],{"trials":2402,"activeCount":99},[],{"intervention":2404,"totalTrials":163,"cells":2405},"CSL730",{"EARLY_PHASE1":2406,"PHASE1":2408,"PHASE2":2427,"PHASE3":2429,"PHASE4":2431,"NA":2433},{"trials":2407,"activeCount":99},[],{"trials":2409,"activeCount":99},[2410,2418],{"nctId":2411,"briefTitle":2412,"status":332,"phases":2413,"primaryCompletion":2414,"completion":2414,"start":2415,"enrollment":847,"conditions":2416,"interventions":2417},"NCT03375606","Assessing the Safety and Tolerability of CSL730 in Healthy Caucasian and Japanese Adults",[88],"2020-06-22","2018-01-10",[1887],[2404],{"nctId":2419,"briefTitle":2420,"status":332,"phases":2421,"primaryCompletion":335,"completion":335,"start":2422,"enrollment":2423,"conditions":2424,"interventions":2426},"NCT04446000","Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneous CSL730 in Healthy Adult Subjects",[88],"2020-09-23",52,[2425],"Immune Complex-mediated Autoimmune Diseases",[2404],{"trials":2428,"activeCount":99},[],{"trials":2430,"activeCount":99},[],{"trials":2432,"activeCount":99},[],{"trials":2434,"activeCount":99},[],{"intervention":2436,"totalTrials":159,"cells":2437},"CSL040",{"EARLY_PHASE1":2438,"PHASE1":2440,"PHASE2":2452,"PHASE3":2454,"PHASE4":2456,"NA":2458},{"trials":2439,"activeCount":99},[],{"trials":2441,"activeCount":99},[2442],{"nctId":2443,"briefTitle":2444,"status":117,"phases":2445,"primaryCompletion":2446,"completion":2446,"start":2447,"enrollment":2448,"conditions":2449,"interventions":2451},"NCT05937581","First-In-Human Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Escalating Single And Multiple Doses Of CSL040 In Healthy Subjects",[88],"2025-12-04","2023-09-28",62,[2450],"Complement-mediated Disorders",[2436],{"trials":2453,"activeCount":99},[],{"trials":2455,"activeCount":99},[],{"trials":2457,"activeCount":99},[],{"trials":2459,"activeCount":99},[],{"intervention":2461,"totalTrials":159,"cells":2462},"rVIIa-FP",{"EARLY_PHASE1":2463,"PHASE1":2465,"PHASE2":2473,"PHASE3":2475,"PHASE4":2477,"NA":2479},{"trials":2464,"activeCount":99},[],{"trials":2466,"activeCount":99},[2467],{"nctId":2468,"briefTitle":2469,"status":117,"phases":2470,"primaryCompletion":1279,"completion":1969,"start":132,"enrollment":719,"conditions":2471,"interventions":2472},"NCT01542619","A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers",[88],[1887],[2461],{"trials":2474,"activeCount":99},[],{"trials":2476,"activeCount":99},[],{"trials":2478,"activeCount":99},[],{"trials":2480,"activeCount":99},[],{"intervention":2482,"totalTrials":159,"cells":2483},"CR002 Liquid API",{"EARLY_PHASE1":2484,"PHASE1":2486,"PHASE2":2495,"PHASE3":2497,"PHASE4":2499,"NA":2501},{"trials":2485,"activeCount":99},[],{"trials":2487,"activeCount":99},[2488],{"nctId":2489,"briefTitle":2490,"status":117,"phases":2491,"primaryCompletion":1028,"completion":1028,"start":1019,"enrollment":1172,"conditions":2492,"interventions":2494},"NCT01347190","Safety and Tolerability Study of Liquid Alpha1 Proteinase Inhibitor (API) in Subjects With Cystic Fibrosis",[88],[2493],"Cystic Fibrosis",[2482],{"trials":2496,"activeCount":99},[],{"trials":2498,"activeCount":99},[],{"trials":2500,"activeCount":99},[],{"trials":2502,"activeCount":99},[],{"intervention":2504,"totalTrials":159,"cells":2505},"Berinert",{"EARLY_PHASE1":2506,"PHASE1":2508,"PHASE2":2517,"PHASE3":2519,"PHASE4":2521,"NA":2523},{"trials":2507,"activeCount":99},[],{"trials":2509,"activeCount":99},[2510],{"nctId":2511,"briefTitle":2512,"status":117,"phases":2513,"primaryCompletion":1784,"completion":1784,"start":1068,"enrollment":730,"conditions":2514,"interventions":2515},"NCT01760343","A Study to Evaluate the Safety and Pharmacokinetics of Two Formulations of C1-esterase Inhibitor",[88],[31],[2504,2516],"CSL830",{"trials":2518,"activeCount":99},[],{"trials":2520,"activeCount":99},[],{"trials":2522,"activeCount":99},[],{"trials":2524,"activeCount":99},[],{"intervention":2516,"totalTrials":159,"cells":2526},{"EARLY_PHASE1":2527,"PHASE1":2529,"PHASE2":2535,"PHASE3":2537,"PHASE4":2539,"NA":2541},{"trials":2528,"activeCount":99},[],{"trials":2530,"activeCount":99},[2531],{"nctId":2511,"briefTitle":2512,"status":117,"phases":2532,"primaryCompletion":1784,"completion":1784,"start":1068,"enrollment":730,"conditions":2533,"interventions":2534},[88],[31],[2504,2516],{"trials":2536,"activeCount":99},[],{"trials":2538,"activeCount":99},[],{"trials":2540,"activeCount":99},[],{"trials":2542,"activeCount":99},[],{"intervention":2544,"totalTrials":159,"cells":2545},"Recombinant anti-granulocyte colony-stimulating factor (G-CSF) receptor monoclonal antibody",{"EARLY_PHASE1":2546,"PHASE1":2548,"PHASE2":2561,"PHASE3":2563,"PHASE4":2565,"NA":2567},{"trials":2547,"activeCount":99},[],{"trials":2549,"activeCount":99},[2550],{"nctId":2551,"briefTitle":2552,"status":117,"phases":2553,"primaryCompletion":2554,"completion":2554,"start":2555,"enrollment":2556,"conditions":2557,"interventions":2560},"NCT03972280","Safety and Pharmacokinetics of Repeat Doses of CSL324 in Subjects With Hidradenitis Suppurativa and Palmoplantar Pustulosis",[88],"2022-10-04","2019-07-04",39,[2558,2559],"Hidradenitis Suppurativa","Palmoplantar Pustulosis",[2544],{"trials":2562,"activeCount":99},[],{"trials":2564,"activeCount":99},[],{"trials":2566,"activeCount":99},[],{"trials":2568,"activeCount":99},[],{"intervention":1962,"totalTrials":159,"cells":2570},{"EARLY_PHASE1":2571,"PHASE1":2573,"PHASE2":2579,"PHASE3":2581,"PHASE4":2583,"NA":2585},{"trials":2572,"activeCount":99},[],{"trials":2574,"activeCount":99},[2575],{"nctId":1957,"briefTitle":1958,"status":117,"phases":2576,"primaryCompletion":1793,"completion":1793,"start":963,"enrollment":1172,"conditions":2577,"interventions":2578},[88],[15],[1950,1962],{"trials":2580,"activeCount":99},[],{"trials":2582,"activeCount":99},[],{"trials":2584,"activeCount":99},[],{"trials":2586,"activeCount":99},[],{"intervention":2588,"totalTrials":159,"cells":2589},"CSL760",{"EARLY_PHASE1":2590,"PHASE1":2592,"PHASE2":2603,"PHASE3":2605,"PHASE4":2607,"NA":2609},{"trials":2591,"activeCount":99},[],{"trials":2593,"activeCount":99},[2594],{"nctId":2595,"briefTitle":2596,"status":332,"phases":2597,"primaryCompletion":2598,"completion":2598,"start":2599,"enrollment":2600,"conditions":2601,"interventions":2602},"NCT04638634","Pharmacokinetics, Safety, and Tolerability of CSL760, an Intravenous Anti-SARS-CoV-2 Hyperimmune Globulin, in Healthy Adult Subjects",[88],"2021-06-09","2021-02-02",12,[1907],[2588],{"trials":2604,"activeCount":99},[],{"trials":2606,"activeCount":99},[],{"trials":2608,"activeCount":99},[],{"trials":2610,"activeCount":99},[],{"intervention":1351,"totalTrials":159,"cells":2612},{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2621,"PHASE3":2623,"PHASE4":2625,"NA":2627},{"trials":2614,"activeCount":99},[],{"trials":2616,"activeCount":99},[2617],{"nctId":1341,"briefTitle":1342,"status":117,"phases":2618,"primaryCompletion":1344,"completion":1345,"start":1346,"enrollment":1347,"conditions":2619,"interventions":2620},[88],[1349],[1351,1334],{"trials":2622,"activeCount":99},[],{"trials":2624,"activeCount":99},[],{"trials":2626,"activeCount":99},[],{"trials":2628,"activeCount":99},[],{"intervention":2630,"totalTrials":159,"cells":2631},"Vamifeport IRF",{"EARLY_PHASE1":2632,"PHASE1":2634,"PHASE2":2647,"PHASE3":2649,"PHASE4":2651,"NA":2653},{"trials":2633,"activeCount":99},[],{"trials":2635,"activeCount":99},[2636],{"nctId":2637,"briefTitle":2638,"status":117,"phases":2639,"primaryCompletion":2640,"completion":2641,"start":2642,"enrollment":1181,"conditions":2643,"interventions":2644},"NCT06726863","Pharmacokinetics and Pharmacodynamics of Two Prolonged-release Formulations of Vamifeport in Healthy Adults",[88],"2025-01-27","2025-02-01","2024-11-22",[513],[2630,2645,2646],"Vamifeport PR1","Vamifeport PR2",{"trials":2648,"activeCount":99},[],{"trials":2650,"activeCount":99},[],{"trials":2652,"activeCount":99},[],{"trials":2654,"activeCount":99},[],{"intervention":2645,"totalTrials":159,"cells":2656},{"EARLY_PHASE1":2657,"PHASE1":2659,"PHASE2":2665,"PHASE3":2667,"PHASE4":2669,"NA":2671},{"trials":2658,"activeCount":99},[],{"trials":2660,"activeCount":99},[2661],{"nctId":2637,"briefTitle":2638,"status":117,"phases":2662,"primaryCompletion":2640,"completion":2641,"start":2642,"enrollment":1181,"conditions":2663,"interventions":2664},[88],[513],[2630,2645,2646],{"trials":2666,"activeCount":99},[],{"trials":2668,"activeCount":99},[],{"trials":2670,"activeCount":99},[],{"trials":2672,"activeCount":99},[],{"intervention":2646,"totalTrials":159,"cells":2674},{"EARLY_PHASE1":2675,"PHASE1":2677,"PHASE2":2683,"PHASE3":2685,"PHASE4":2687,"NA":2689},{"trials":2676,"activeCount":99},[],{"trials":2678,"activeCount":99},[2679],{"nctId":2637,"briefTitle":2638,"status":117,"phases":2680,"primaryCompletion":2640,"completion":2641,"start":2642,"enrollment":1181,"conditions":2681,"interventions":2682},[88],[513],[2630,2645,2646],{"trials":2684,"activeCount":99},[],{"trials":2686,"activeCount":99},[],{"trials":2688,"activeCount":99},[],{"trials":2690,"activeCount":99},[],{"intervention":2692,"totalTrials":159,"cells":2693},"Human beta common receptor antagonist monoclonal antibody",{"EARLY_PHASE1":2694,"PHASE1":2696,"PHASE2":2708,"PHASE3":2710,"PHASE4":2712,"NA":2714},{"trials":2695,"activeCount":99},[],{"trials":2697,"activeCount":99},[2698],{"nctId":2699,"briefTitle":2700,"status":117,"phases":2701,"primaryCompletion":2702,"completion":2702,"start":2703,"enrollment":2704,"conditions":2705,"interventions":2707},"NCT04082754","A Clinical Study to Test the Safety, Exposure, and Pharmacodynamic Markers of CSL311 in Patients With Mild-to-moderate Asthma and in Healthy Volunteers",[88],"2023-11-14","2019-11-28",78,[2706],"Asthma",[2692],{"trials":2709,"activeCount":99},[],{"trials":2711,"activeCount":99},[],{"trials":2713,"activeCount":99},[],{"trials":2715,"activeCount":99},[],{"intervention":2717,"totalTrials":159,"cells":2718},"Autologous enriched CD34+ cell fraction that contains CD34+ cells transduced with lentiviral vector encoding human γ-globinG16D and short-hairpin RNA734",{"EARLY_PHASE1":2719,"PHASE1":2721,"PHASE2":2732,"PHASE3":2734,"PHASE4":2736,"NA":2738},{"trials":2720,"activeCount":99},[],{"trials":2722,"activeCount":99},[2723],{"nctId":2724,"briefTitle":2725,"status":332,"phases":2726,"primaryCompletion":2727,"completion":2727,"start":2728,"enrollment":159,"conditions":2729,"interventions":2731},"NCT04091737","CSL200 Gene Therapy in Adults With Severe Sickle Cell Disease",[88],"2021-05-05","2019-10-02",[2730],"Anemia, Sickle Cell",[2717],{"trials":2733,"activeCount":99},[],{"trials":2735,"activeCount":99},[],{"trials":2737,"activeCount":99},[],{"trials":2739,"activeCount":99},[],{"intervention":2741,"totalTrials":19,"cells":2742},"CSL312",{"EARLY_PHASE1":2743,"PHASE1":2745,"PHASE2":2766,"PHASE3":2778,"PHASE4":2806,"NA":2808},{"trials":2744,"activeCount":99},[],{"trials":2746,"activeCount":99},[2747,2756],{"nctId":2748,"briefTitle":2749,"status":117,"phases":2750,"primaryCompletion":2751,"completion":2751,"start":2752,"enrollment":2753,"conditions":2754,"interventions":2755},"NCT04580654","A Study to Assess the Pharmacokinetics and Safety of CSL312 in Healthy Japanese and Caucasian Adults",[88],"2021-05-07","2020-10-29",38,[513],[2741],{"nctId":2757,"briefTitle":2758,"status":117,"phases":2759,"primaryCompletion":2760,"completion":2760,"start":2761,"enrollment":2762,"conditions":2763,"interventions":2765},"NCT05306275","A Study to Compare the Pharmacokinetics of CSL312 Administered by Prefilled Syringe Assembled to Autoinjector to the Pharmacokinetics Administered by Prefilled Syringe Assembled to Needle Safety Device in Healthy Subjects",[88],"2022-09-27","2022-04-04",132,[2764],"Healthy Participants",[2741],{"trials":2767,"activeCount":99},[2768],{"nctId":2769,"briefTitle":2770,"status":107,"phases":2771,"primaryCompletion":2772,"completion":2773,"start":2774,"enrollment":99,"conditions":2775,"interventions":2777},"NCT04281524","A Clinical Study to Test the Efficacy and Safety of CSL312 on Catheter-associated Blood Clot Formation in Subjects With Cancer Who Receive Chemotherapy Through a PICC Line",[88,89],"2021-08","2021-10","2020-03",[2776],"PICC-associated Thrombosis",[2741],{"trials":2779,"activeCount":99},[2780,2788,2797],{"nctId":2781,"briefTitle":2782,"status":117,"phases":2783,"primaryCompletion":2784,"completion":2784,"start":2785,"enrollment":477,"conditions":2786,"interventions":2787},"NCT04656418","CSL312 (Garadacimab) in the Prevention of Hereditary Angioedema Attacks",[90],"2022-06-07","2021-01-27",[23],[2741],{"nctId":2789,"briefTitle":2790,"status":117,"phases":2791,"primaryCompletion":2792,"completion":2792,"start":2793,"enrollment":1181,"conditions":2794,"interventions":2796},"NCT05819775","CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema",[90],"2025-11-19","2023-05-30",[2795],"Hereditary Angioedema (HAE)",[2741],{"nctId":2798,"briefTitle":2799,"status":117,"phases":2800,"primaryCompletion":2801,"completion":2801,"start":2802,"enrollment":2803,"conditions":2804,"interventions":2805},"NCT04739059","Long-term Safety and Efficacy of CSL312 (Garadacimab) in the Prophylactic Treatment of Hereditary Angioedema Attacks",[90],"2025-11-21","2021-03-29",171,[23],[2741],{"trials":2807,"activeCount":99},[],{"trials":2809,"activeCount":99},[2810],{"nctId":2811,"briefTitle":2812,"status":2813,"phases":2814,"conditions":2815,"interventions":2816},"NCT07159464","Post Study Access of CSL312 (Garadacimab) for Pediatric Participants With Hereditary Angioedema Who Have Completed the CSL312_3003 Study","AVAILABLE",[],[2795],[2741],{"intervention":1217,"totalTrials":307,"cells":2818},{"EARLY_PHASE1":2819,"PHASE1":2821,"PHASE2":2823,"PHASE3":2825,"PHASE4":2835,"NA":2837},{"trials":2820,"activeCount":99},[],{"trials":2822,"activeCount":99},[],{"trials":2824,"activeCount":99},[],{"trials":2826,"activeCount":99},[2827,2831],{"nctId":1208,"briefTitle":1209,"status":117,"phases":2828,"primaryCompletion":1211,"completion":1212,"start":1213,"enrollment":1214,"conditions":2829,"interventions":2830},[90],[327],[1217,1197],{"nctId":1219,"briefTitle":1220,"status":117,"phases":2832,"primaryCompletion":1222,"completion":1222,"start":739,"enrollment":1223,"conditions":2833,"interventions":2834},[90],[872,326],[1217,1197],{"trials":2836,"activeCount":99},[],{"trials":2838,"activeCount":99},[2839],{"nctId":2840,"briefTitle":2841,"status":117,"phases":2842,"primaryCompletion":1501,"completion":1501,"start":1256,"enrollment":2843,"conditions":2844,"interventions":2848},"NCT01053169","Observational Study of Prophylaxis and Treatment of Acute Perioperative Bleeding With Beriplex® P\u002FN (Probe Study)",[],445,[2845,2846,2847],"Coagulation Protein Disorders","Blood Loss, Surgical","Perioperative Care",[1217,2849],"Fresh Frozen Plasma (FFP) and Beriplex® P\u002FN",{"intervention":2851,"totalTrials":163,"cells":2852},"AAV5-hFIX",{"EARLY_PHASE1":2853,"PHASE1":2855,"PHASE2":2857,"PHASE3":2868,"PHASE4":2870,"NA":2872},{"trials":2854,"activeCount":99},[],{"trials":2856,"activeCount":99},[],{"trials":2858,"activeCount":99},[2859],{"nctId":2860,"briefTitle":2861,"status":117,"phases":2862,"primaryCompletion":2863,"completion":2863,"start":2864,"enrollment":2865,"conditions":2866,"interventions":2867},"NCT02396342","Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B",[88,89],"2021-04-15","2015-06-10",10,[15],[2851],{"trials":2869,"activeCount":99},[],{"trials":2871,"activeCount":99},[],{"trials":2873,"activeCount":99},[2874],{"nctId":2875,"briefTitle":2876,"status":117,"phases":2877,"primaryCompletion":2878,"completion":2878,"start":2879,"enrollment":1347,"conditions":2880,"interventions":2881},"NCT05360706","Study of AAV5-hFIX in Severe or Moderately Severe Haemophilia B",[],"2026-03-26","2021-03-18",[15],[2851],{"intervention":2883,"totalTrials":159,"cells":2884},"Kcentra®",{"EARLY_PHASE1":2885,"PHASE1":2887,"PHASE2":2889,"PHASE3":2891,"PHASE4":2893,"NA":2895},{"trials":2886,"activeCount":99},[],{"trials":2888,"activeCount":99},[],{"trials":2890,"activeCount":99},[],{"trials":2892,"activeCount":99},[],{"trials":2894,"activeCount":99},[],{"trials":2896,"activeCount":99},[2897],{"nctId":2898,"briefTitle":2899,"status":117,"phases":2900,"primaryCompletion":2901,"completion":2901,"start":2902,"enrollment":2903,"conditions":2904,"interventions":2906},"NCT02319460","An Observational Cohort Study to Investigate the Risk of Thromboembolic Events in Patients Receiving Kcentra® or Plasma to Reverse Vitamin K Antagonist (VKA) Therapy in the Setting of Acute Major Bleeding",[],"2020-06-30","2014-04-24",2238,[2905],"Hemorrhage",[2883,2907],"Plasma",{"intervention":2907,"totalTrials":159,"cells":2909},{"EARLY_PHASE1":2910,"PHASE1":2912,"PHASE2":2914,"PHASE3":2916,"PHASE4":2918,"NA":2920},{"trials":2911,"activeCount":99},[],{"trials":2913,"activeCount":99},[],{"trials":2915,"activeCount":99},[],{"trials":2917,"activeCount":99},[],{"trials":2919,"activeCount":99},[],{"trials":2921,"activeCount":99},[2922],{"nctId":2898,"briefTitle":2899,"status":117,"phases":2923,"primaryCompletion":2901,"completion":2901,"start":2902,"enrollment":2903,"conditions":2924,"interventions":2925},[],[2905],[2883,2907],{"intervention":2927,"totalTrials":159,"cells":2928},"FCH",{"EARLY_PHASE1":2929,"PHASE1":2931,"PHASE2":2933,"PHASE3":2935,"PHASE4":2937,"NA":2939},{"trials":2930,"activeCount":99},[],{"trials":2932,"activeCount":99},[],{"trials":2934,"activeCount":99},[],{"trials":2936,"activeCount":99},[],{"trials":2938,"activeCount":99},[],{"trials":2940,"activeCount":99},[2941],{"nctId":2942,"briefTitle":2943,"status":117,"phases":2944,"primaryCompletion":2945,"completion":2945,"start":2946,"enrollment":1181,"conditions":2947,"interventions":2949},"NCT02427217","An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency",[],"2017-12-06","2015-05-07",[2948],"Congenital Fibrinogen Deficiency",[2927],{"intervention":2951,"totalTrials":159,"cells":2952},"Subcutaneous IgG",{"EARLY_PHASE1":2953,"PHASE1":2955,"PHASE2":2957,"PHASE3":2959,"PHASE4":2961,"NA":2963},{"trials":2954,"activeCount":99},[],{"trials":2956,"activeCount":99},[],{"trials":2958,"activeCount":99},[],{"trials":2960,"activeCount":99},[],{"trials":2962,"activeCount":99},[],{"trials":2964,"activeCount":99},[2965],{"nctId":2966,"briefTitle":2967,"status":117,"phases":2968,"primaryCompletion":2969,"completion":2969,"start":1256,"enrollment":121,"conditions":2970,"interventions":2971},"NCT01166074","Retrospective Chart Review of Subcutaneous IgG Use in Infants",[],"2010-12",[26],[2951],{"intervention":2973,"totalTrials":159,"cells":2974},"Afstyla®",{"EARLY_PHASE1":2975,"PHASE1":2977,"PHASE2":2979,"PHASE3":2981,"PHASE4":2983,"NA":2985},{"trials":2976,"activeCount":99},[],{"trials":2978,"activeCount":99},[],{"trials":2980,"activeCount":99},[],{"trials":2982,"activeCount":99},[],{"trials":2984,"activeCount":99},[],{"trials":2986,"activeCount":99},[2987],{"nctId":2988,"briefTitle":2989,"status":117,"phases":2990,"primaryCompletion":2991,"completion":2991,"start":2992,"enrollment":2448,"conditions":2993,"interventions":2995},"NCT04675541","Register of Patients With haEmophilia A tReated With Afstyla®",[],"2024-12-31","2018-09-24",[2994],"Haemophilia A",[2973],{"intervention":2997,"totalTrials":159,"cells":2998},"Rabies Vaccine",{"EARLY_PHASE1":2999,"PHASE1":3001,"PHASE2":3003,"PHASE3":3005,"PHASE4":3007,"NA":3009},{"trials":3000,"activeCount":99},[],{"trials":3002,"activeCount":99},[],{"trials":3004,"activeCount":99},[],{"trials":3006,"activeCount":99},[],{"trials":3008,"activeCount":99},[],{"trials":3010,"activeCount":99},[3011],{"nctId":3012,"briefTitle":3013,"status":117,"phases":3014,"primaryCompletion":1256,"completion":1256,"start":783,"enrollment":3015,"conditions":3016,"interventions":3018},"NCT01063140","Rabies Immune Plasma Booster Study",[],491,[3017],"Rabies",[2997,2997],{"intervention":3020,"totalTrials":159,"cells":3021},"Berinert®",{"EARLY_PHASE1":3022,"PHASE1":3024,"PHASE2":3026,"PHASE3":3028,"PHASE4":3030,"NA":3032},{"trials":3023,"activeCount":99},[],{"trials":3025,"activeCount":99},[],{"trials":3027,"activeCount":99},[],{"trials":3029,"activeCount":99},[],{"trials":3031,"activeCount":99},[],{"trials":3033,"activeCount":99},[3034],{"nctId":3035,"briefTitle":3036,"status":117,"phases":3037,"primaryCompletion":3038,"completion":3038,"start":1007,"enrollment":3039,"conditions":3040,"interventions":3042},"NCT01108848","Patient Registry Study of Berinert® in Normal Clinical Practice",[],"2014-04",318,[3041],"Includes: Hereditary Angioedema",[3020],{"intervention":2849,"totalTrials":159,"cells":3044},{"EARLY_PHASE1":3045,"PHASE1":3047,"PHASE2":3049,"PHASE3":3051,"PHASE4":3053,"NA":3055},{"trials":3046,"activeCount":99},[],{"trials":3048,"activeCount":99},[],{"trials":3050,"activeCount":99},[],{"trials":3052,"activeCount":99},[],{"trials":3054,"activeCount":99},[],{"trials":3056,"activeCount":99},[3057],{"nctId":2840,"briefTitle":2841,"status":117,"phases":3058,"primaryCompletion":1501,"completion":1501,"start":1256,"enrollment":2843,"conditions":3059,"interventions":3060},[],[2845,2846,2847],[1217,2849],{"intervention":3062,"totalTrials":159,"cells":3063},"Voncento®",{"EARLY_PHASE1":3064,"PHASE1":3066,"PHASE2":3068,"PHASE3":3070,"PHASE4":3072,"NA":3074},{"trials":3065,"activeCount":99},[],{"trials":3067,"activeCount":99},[],{"trials":3069,"activeCount":99},[],{"trials":3071,"activeCount":99},[],{"trials":3073,"activeCount":99},[],{"trials":3075,"activeCount":99},[3076],{"nctId":3077,"briefTitle":3078,"status":117,"phases":3079,"primaryCompletion":3080,"completion":3080,"start":3081,"enrollment":3082,"conditions":3083,"interventions":3084},"NCT04657887","Registry of Patients With Von WilLEbrand Disease Treated With Voncento®",[],"2023-12-31","2015-11-23",135,[18],[3062]]